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Abstract
Psoriatic arthritis (PsA) is a chronic inflammatory artlnitis. It affects approximately 0.05% 
o f the general population presenting as peripheral arthritis, axial disease or a combination 
o f both. About 10% o f patients with psoriasis suffer from PsA. Currently available 
therapies have limited efficacy with associated toxicity. PsA is therefore a common 
artlnopathy for which novel therapies are urgently required.
Our understanding o f the role of the immune system in the pathogenesis o f rheumatic 
disease has led to the development o f specific targeted therapies. The identification of 
tumour necrosis factor alpha (TNFa) as a key player in the inflammatory response has 
been a major advance in the field of rheumatology. The effects of blocking this pro 
inflammatory molecule have resulted in dramatic clinical effects across the spectrum of 
rheumatic diseases. Unfortunately however there remain a proportion o f non-responders 
and concerns have been raised surrounding the adverse effects of these therapies (Furst, 
Keystone et al. 2001). It is therefore important to continue to elucidate other key players in 
the inflammatory cascade that can be modified to achieve clinical response.
A critical advance in understanding the immune system’s role in driving inflammation has 
been the recognition o f different functional subsets of T helper (Th) cells according to their 
cytokine profile. Interferon gamma (IFNy), a potent stimulator o f TN Fa production, is the 
hallmark cytokine of the T helper type 1 (Thl) immune response whereas T helper 2 (Th2) 
responses are characterised by the production of anti-inflammatory cytokines such as IL-4, 
IL-5 and IL-10. Thl mediated diseases such as psoriasis may benefit from therapies that 
direct the immune system towards a Th2 immune response (Ockenfels, Schultewolter et al.
1998). Furthermore identifying those factors that regulate Thl immune responses may lead 
to specifically targeted therapies in the clinic.
Initial studies o f cytokine profiles in PsA synovial fluid (SF) demonstrated an increase in 
Thl cytokines (Partsch, Wagner et al. 1998) (Ritchlin, Haas-Smith et al. 1998). Subsequent 
data have since emerged suggesting T hl cytokines such as IFNy are more prominent in 
rheumatoid arthritis (RA) than in seronegative arthropathies including PsA (Canete, 
Martinez et al. 2000). The issue surrounding the predominant T cell response in PsA is 
controversial and clarification is required.
Techniques have evolved that enable us to achieve clarification o f a true in vivo Thl 
response by identifying cells in SF that spontaneously secrete IFNy. In this thesis, 
spontaneously secreting cells were identified in SF o f patients with active PsA. That such 
IFNy expressing cells may have a pathogenic role in PsA is supported by the following 
observations;
• IFNy is the prototype macrophage activator of TN Fa that drives inflammation in 
psoriasis and PsA.
• IFNy when tested as a potential treatment for psoriasis induced synovitis in a subset of 
patients. (O'Connell, Gerber et al. 1992)
• The injection o f IFNy into the skin induces hyperkeratosis (Fierlbeck, Rassner et al. 
1990)
• Autologous Natural Killer T (NKT) cells, potent producers o f IL-4 and IFNy, are able 
to induce psoriasis in ‘normal skin’ grafted onto a SCID mouse (Nickoloff, Wrone- 
Smith et al. 1999).
Those factors regulating the expression o f IFNy may therefore be o f considerable interest 
as they may offer potential targets to modify Thl responses in PsA.
Cytokines such as interleukin 18 (IL-18) and interleukin 12 (IL-12) have been shown to 
regulate Thl responses in animal models o f arthritis (Leung, Mclnnes et al. 2000). 
Whether such cytokines are present and indeed induce inflammation in PsA is unknown. 
The first part of this thesis focuses on the characterisation of the predominant Th response 
in PsA and the identification o f key regulatory cytokines such as IL-12 and IL-18 that may 
drive TN Fa production and as such lead to inflammation.
The presence of other regulatory cells capable o f driving the inflammatory response was 
explored briefly. NKT cells are a subset of T cell, which secrete IFNy and IL-4 depending 
on the predominant cytokine milieu (Hafner, Falk et al. 1999). A pathogenic role for NKT 
cells in psoriasis has been suggested. (Bonish, Jullien et al. 2000). The ability of synovial 
fluid mononuclear cells (SF MC) to proliferate and secrete TN Fa in response to glycolipid 
presented to NK T cells was investigated.
Although TN Fa contributes directly to synovial inflammation, the blockade of TN Fa does 
not protect completely against cartilage damage (Joosten, Helsen et al. 1999). IFNy and IL- 
17 have opposing effects on bone resorption. IFNy inliibits bone resorption whereas IL-17 
entrances resorption thi'ough the degradation or enliancement o f TNF receptor associated 
factor 6 (TRAF6) respectively (Chabaud, Lubberts et al. 2001). The expression of IL-17 
and the functional effects o f this cytokine on MMP3 expression by fibroblasts were 
therefore studied as a final section in this thesis.
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Chapter 1 Introduction 
1.1 Psoriatic arthritis
1.1.1 History
The earliest reports o f psoriatic artlnitis (PsA) come from visual, radiological and 
microscopy studies o f skeletal remains recovered from tombs in the Byzantine Monastery 
in the Judean Desert. During the Byzantine period extending from 395-1453 A.D, the 
earlier practise o f expelling those with disfiguring diseases evolved into a caring 
philosophy where the sick were housed and fed out of charity, often within monasteries. 
The presence o f these skeletal remains confirms earlier suggestions that psoriasis was one 
o f the diseases included by those in the ancient eastern Mediterranean under the term of 
biblical leprosy (Zias and Mitchell 1996). The earliest reports o f PsA in Britain are from 
skeletal remains of a thirteenth century male with ankylosis o f the interphalangeal joints 
and typical ‘cup and pencil’ deformity o f the distal interphalangeal joints indicative o f PsA 
(Rogers, Watt et al. 1981).
Despite observations o f an association between psoriasis and arthritis in 1818 by the 
French physician Baron Jean Louis Alibert, it was not until 1860 that the French 
dermatologist Bazin coined the term PsA. Over the next 100 years many individual cases 
o f psoriasis and arthritis were described in the literature until 1950 when PsA was accepted 
as a distinct clinical entity (O'Neill and Silman 1994).
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1.1.2 Epidemiology and aetiology
Research into PsA is hampered by lack o f a validated case definition. Epidemiological 
studies indicate that PsA is a unique arthi'opathy rather than a chance association o f 
cutaneous and joint inflammation (Baker 1966). The prevalence o f PsA in different 
populations varies depending on diagnostic criteria employed. Defining PsA using the 
American Rheumatism Association criteria for RA plus a feature typical o f PsA indicates a 
prevalence o f 0.02-0.05% in the general population (Hellgren 1970) (van Romunde, 
Valkenburg et al. 1984). Moll and Wright using more permissive criteria calculated a 
prevalence o f 0.1% from a hospital study and a prevalence of psoriasis of 1.5% in the 
general population (Moll, Johnson et al. 1974). A population based study in Olmstead 
County identified 1056 patients with psoriasis of whom 6.25% had arthritis with a point 
prevalence o f 0.1% (Shbeeb, Uramoto et al. 2000). The peak incidence of PsA occurs 
between the ages 20-40 years with a slight male bias except in the subset o f patients with 
symmetrical polyarthritis where females predominate (Veale 2000).
The prevalence of psoriasis is quoted regularly to be approximately 2%. This statistic is 
based on rough estimates, as there have been few defined population based studies 
(Christophers 2001). The existence o f geographical and racial differences has however 
been clearly defined with lower prevalence in certain ethnic groups including African, 
African-Americans, Latin American Indians and Orientals. Sunlight exposure could alter 
case acquisition or alternatively environmental factors may truly operate. The prevalence 
o f psoriasis is similar in both men and women although women develop the disease earlier 
especially in the presence of a positive family history (tiolgate 1975).
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The precise aetiology o f PsA and psoriasis remains unclear however most data suggest a 
combination o f genetic and enviromnental factors.
Genetic contribution- The genetics o f PsA and psoriasis are complex with polygenic, 
multifactorial characteristics o f inheritance leading to variable penetrance, familial 
occumence and age of onset. They share a common genetic background however there are 
few studies that have stratified psoriasis patients for the presence o f PsA.
In psoriasis, familial aggregation was first noted in 1967 (Montagnanl and Rossi 1969). 
Type 1 psoriasis, characterised by familial early age of onset, has a strong association to 
MHC genes whereas type 2 occurs sporadically in older individuals with no family history 
(Henseler 1998). Accordingly, PsA patients with type 1 psoriasis show PILA associations 
similar to type 1 patients without arthritis but different from those with arthritis and late 
onset disease (Raliman, Schentag et al. 1999).
Evidence for family and twin studies suggest that psoriasis has a strong genetic component. 
In a study o f more than 3500 families with one, or both parents affected by psoriasis, the 
lifetime risk o f developing psoriasis if  none, one or both parents had psoriasis was 
calculated at 0.04, 0.28 and 0.65 respectively (Swanbeck, Inerot et al. 1997). This risk was 
increased if  there was already an affected child in the family.
Studies on monozygotic twins have shown concordance o f psoriasis o f 35% to 70% 
compared with 12% to 20% in dyzygotic twins corresponding to a hereditability of 80% to 
90% (Duffy, Spelman et al. 1993). In contrast to dizygotic twins, monozygotic twins
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concordant for the disease tend to have a similar disease course, age of onset and body 
distribution (Brandrup, Holm et al. 1982).
There is much controversy regarding the mode of inheritance of psoriasis. Results from 
genome-wide linkage studies suggest that it is a multigenic disease with considerable 
genetic heterogeneity in different groups. In some groups, the disease appears to be caused 
by a dominantly acting susceptibility allele (Matthews, Fry et al. 1996), whereas in others 
the pattern of familial occun*ence is compatible with an autosomal trait (Swanbeck, Inerot 
et al. 1995).
Genome wide scans using micro satellite markers have identified various cliromosomal 
regions associated with psoriasis. HLA-B13, HLA-Cw6 and HLA-B57 were the first to be 
recognised in association with psoriasis. HLA-Cw6 is associated with early disease. 
(Bhalerao and Bowcock 1998). Subsequent family studies identified different disease 
associated haplotypes : Cw6-B57, Cw6-B13 and Cw8-B65 in Caucasian patients as well 
as Cw6-B37 in Japanese and Korean patients suggesting a common psoriasis susceptibility 
gene/locus close to HLA-C common to these different haplotypes (Jenisch, Westphal et al. 
1999). Despite this, only 10% o f HLA-Cw6 positive individuals will develop psoriasis. In 
non-Bantu speaking Western Africans, the incidence of psoriasis is low despite a relatively 
high frequency o f HLA-Cw6 and HLA-B27 (Leder and Farber 1997).
Genome scans have identified a variety o f susceptibility loci including chromosome Iq, 3q, 
4q and 19q. Weaker associations have been identified such as 16q however this is of 
particular interest as markers close to chromo some 16q have strong associations with 
ankylosing spondylitis and Crolins disease. Case controlled studies indicate the prevalence 
of psoriasis is increased in patients with Crolms (Lee, Bellary et al. 1990). Furthermore
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patients with psoriasis and Crohns are more likely to develop spondyloarthropathy 
suggesting 16q may be an important susceptibility marker for PsA.
In 1973 familial aggregation was noted in PsA (Moll and Wright 1973). Data obtained in a 
Swedish patient cohort indicate that gene(s) located within a susceptibility region near 
Cw6 determine a distinct phenotype with an early age of onset (Enerback, Martinsson et al.
1997). Few specific HLA associations have been described for PsA per se however 
associations have been described for peripheral arthritis (B38, B39), symmetrical 
polyarthritis (DR4), spinal arthritis (B27) and juvenile PsA (A2) (Eastmond 1994). An 
association has been described between poor prognosis in PsA and HLA B39 (Gladman, 
Farewell et al. 1998).
The association o f HLA and susceptibility to PsA may be due to NK cell interaction with 
their respective HLA class I ligands via killer Ig-like receptors (KIR). Independent 
segregation o f HLA and KIR genes, along with KIR specificity for particular HLA 
allotypes raises the possibility that any given individual may express KIR molecules for 
which no ligand is present. Both activating and inhibitory KIR genes have been described. 
Increased susceptibility to developing PsA occurs in the presence o f activating genes when 
HLA ligands for homologous inhibitory receptors are missing (Martin, Nelson et al. 2002). 
In contrast, studies o f MHC and T cell receptor gene polymorphisms found no association 
with disease expression (Sakkas, Loqueman et al. 1990).
Functional cytokine gene polymorphisms (TN Fa-302 and TNF(3+ 252) have recently been 
associated with age o f onset o f psoriasis, erosive disease and radiological progression 
supporting the rationale for the use o f anti TNF based therapies in patients with severe 
disease (Balding, Kane et al. 2003).
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Environmental influences on immune function are potentially wide-ranging. Infection has 
proved to be of major interest. Other potential influences however include stress, 
ultraviolet light, toxins, dietary factors, and radiation exposure. No good epidemiological 
studies of sufficient power have yet addressed such diversity.
Infection -Infectious environmental triggers such as p-haemolytic streptococci and HIV 
are closely related to PsA and psoriasis, however, a true pathogenic role for these agents is 
not proven (Espinoza, Berman et al. 1988) (Vasey, Deitz et al. 1982). Expression o f PsA in 
HIV may be due to T cell dysregulation or regulatory T cell loss. Susceptibility factors for 
the development o f psoriasis and PsA following infection have not been identified; in Sub- 
Saharan Africa, HIV associated PsA has no association with HLA B27 (Njobvu, McGill et 
al. 1998).
Trauma -The role o f trauma in the aetiology of PsA has been implicated in significantly 
more cases compared with other forms of arthritis (Punzi, Pianon et al. 1998) (Langevitz, 
Buskila et al. 1990). The well-characterised Koebner phenomenon is characterised by the 
appearance of psoriasis following cutaneous trauma. Whether a ‘deep’ Koebner 
phenomenon could account for trauma induced PsA has not been proven. As will be 
discussed later this is an attractive hypothesis to explain enthesial localisation. 
Neuroendocrine; Substance P (SP), a powerful vasoactive, pro-inflammatory neuropeptide, 
may offer an explanation for the association o f trauma and arthritis or even for other 
neuropsychiatrie effects. In one case report, a patient with long-standing hemiplegia, 
developed unilateral psoriatic arthritis and psoriasis on the non-hemiplegic side only
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(Veale, Farrell et al. 1993). SP release requires an intact nervous system hence failure to 
release SP from damaged nerve endings may inhibit the inflammatory response.
In summary however it is currently likely that the best opportunity to resolve aetiology lies 
in fully evaluating and rationalising the pathogenesis o f the psoriatic skin and synovial 
lesions themselves. This is a strong driver for this thesis.
1.1.3 Clinical aspects
PsA
Despite previous beliefs that PsA is a benign form o f inflammatory artliritis, several data 
demonstrate premature mortality similar to RA (Wong, Gladman et al. 1997). Deaths are 
attributed to cardiovascular disease (36%), respiratory disease (21%), malignant neoplasm 
(17%), and to injury or poisonings (14.9%). Furthermore PsA is recognised to cause 
progressive functional decline associated with considerable social and financial costs 
(Husted, Gladman et al. 2001). Whether PsA carries the same cardiovascular risks as RA 
and hence shared vascular risk factors is currently unclear.
PsA develops in 5-25% of patients with psoriasis (Patel, Veale et al. 2001). In 15% of 
cases, the disease develops simultaneously in skin and joints. In 60% o f cases the onset of 
psoriasis precedes arthritis and in 25% the reverse occurs (PsA sine psoriasis) (Pitzalis
1998). The clinical syndrome is therefore clearly a continuum -  this in turn has major 
implications for pathogenic studies.
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The absence o f validated criteria for classification is due partly to the heterogeneous 
clinical features associated with the disease, and the relapsing and remitting nature of both 
psoriasis and arthritis. Clinical subgroups have been proposed and have proved useful in 
study o f the disease. However, there remain inconsistencies in published data.
Moll and Wright described 5 clinical patterns of joint involvement in the late 1970s (Moll 
1979). This classification has largely been abandoned as more recent studies have shown 
that patients can present with more than one pattern that may change over time (Khan and 
Gladman 2003). Alternative classifications have been suggested based on the presence of 
axial disease with or without peripheral joint involvement (Marsal, Armadans-Gil et al.
1999) or the presence or absence o f extra osseous manifestations (Helliwell, Marchesoni et 
al. 1991). Clinical variants o f osseous disease in PsA include onycho-pachydermo- 
periostitis and the SAPHO syndrome. The initial obseiwation that osteoperiostitis o f the 
first DIP joint o f the foot was associated with nail disease and destructive joint disease o f 
the feet led to the term psoriatic onycho-pachydermo-periostitis. This variant is 
characterised by painful onychopathy, soft tissue swelling and bone erosions. There have 
been 10 cases reported to date in France (Boisseau-Garsaud, Beylot-Barry et al. 1996). 
There is debate as to whether the SAPHO syndrome (synovitis, acne, pustulosis, 
hyperostosis and osteitis) is a true variant o f PsA or an unrelated condition (Dumolard, 
Gaudin et al. 1999). Pustulotic arthritis more commonly involves the sternoclavicular 
joints with monoarticular or oligoarticular peripheral joint involvement.
24
Characteristic features o f PsA include distal interphalangeal (DIP) involvement, 
enthesopathy, spondylitis and dactylitis. The presence o f skin and nail involvement, the 
absence o f rheumatoid factor (RF) and rheumatoid nodules help to differentiate it from 
RA. Nail lesions indicate a higher risk o f psoriatic patients developing DIP involvement. 
(Cohen, Reda et al. 1999). Nail pitting and onycholysis are observed in 86.5% of patients 
affected by PsA (Lavaroni, Kokelj et al. 1994). The latter can be differentiated from a 
fungal infection by analysis o f nail scrapings.
There are no diagnostic laboratory tests in PsA. Standard markers such as ESR and CRP 
are elevated in active disease in some patients only (Helliwell, Marchesoni et al. 1991). 
Anaemia may arise as a result of chronic disease or from secondary iron deficiency.
Both antinuclear antibodies (ANA) and RF are found in up to 10% of patients with PsA. In 
this latter subset, patients with symmetrical disease are difficult to differentiate from RA 
with co-existing psoriasis. Such antibodies also occur in patients with psoriasis 
uncomplicated by arthritis, and are likely to reflect immune dysregulation rather than 
specific autoimmunity.
The spectrum o f articular presentations in PsA poses particular problems in assessing 
disease progress and response to drug therapies with implications for clinical trial design 
and for ex vivo pathogenic studies. Despite these drawbacks, such patterns of disease may 
offer clues to the pathogenesis o f joint destruction. Those with severe mutilating arthritis 
clearly have different bone resorptive processes than those with predominantly axial 
disease with osteophyte formation. For example the simultaneous process o f bone 
resoiption and formation may explain the characteristic radiological ‘pencil in cup’
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deformities. This variation in clinical phenotype may be explained partly by variable 
immune pathogenic influences. The expanding field of osteo-immunology will shed light 
on such possibilities.
Psoriasis
Psoriasis, a chronic relapsing disorder o f skin and nails, is the defining extra-articular 
feature o f PsA. Most patients with PsA have the classic psoriasis vulgaris pattern of skin 
lesions, consisting o f well-demarcated erythematous plaques with superficial silver scaling 
present in extensor aspects of the limbs and trunk. The skin lesions may be minimal or 
concealed especially in areas such as the scalp, ears, buttocks or umbilicus. While severe 
psoriasis has been associated with a higher prevalence of PsA (Stern 1985), there is no 
direct temporal relationship between the severity of skin and joint inflammation.
Psoriasis can be classified by lesional morphology and the presence of pustular and non- 
pustular forms. Acute and chronic varieties are described. As in PsA, the phenotype may 
change over time reflecting a spectrum o f disease expression. A characteristic feature o f 
psoriasis is the tendency to relapse. While some patients relapse within months or even 
weeks others may remain in remission for many years. The former tend to develop more 
severe disease with rapidly enlarging lesions. Disease severity is based on the extent o f 
body involvement, degree o f erythema, induration and scale. This provides a composite 
index of psoriasis area and severity (PASI) that is used primarily in clinical trials to assess 
therapeutic response.
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1.1.4 Imaging in PsA
Radiographic changes in the synovial joints, tendon and ligament insertions, axial skeleton 
and sacroiliac joints are seen in two thirds o f patients with PsA. Plain radiographs o f the 
hands and feet yield most information with soft tissue swelling a common feature. 
Periarticular osteopaenia and erosions, joint space narrowing and periostitis are other 
characteristic features. Gross destruction of isolated joints and the occurrence of both joint 
lysis and ankylosis the so called ‘pencil in cup’ deformity, are other typical features of PsA 
(Gladman 1998).
In the axial skeleton, the commonest site of involvement is the sacroiliac joint. Unilateral 
or marked asymmetrical involvement is seen more commonly than in ankylosing 
spondylitis (AS) but fusion is uncommon. In the lumbar spine, osteitis and squaring are 
less common than in AS. In the thoracolumbar spine, paramarginal asymmetrie bulky 
osteophytes are characteristic and may appear in the absence o f sacroiliac disease.
The reported frequency o f joint involvement in PsA depends on the imaging technique 
employed. More sensitive techniques such as magnetic resonance imaging (MR!) and 
ultrasound yield a higher incidence of involvement than conventional radiology 
(McGonagle, Conaghan et al. 1999) (Me Gonagle, Gibbon et al. 1999) (Azouz and Duffy 
1995) (Balint and Sturrock 2000). MRI is superior to conventional radiology, as it is 
capable o f providing contrasting images o f skeletal and soft tissues. The intensity of the 
emitted resonance signal from any given point in the patient is dependent on several factors 
including the hydrogen density and unique magnetic properties - T1 and T2 weighting. 
This property o f MRI renders it capable o f detecting inflammation in the adjacent bone
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marrow and soft tissue around the synovial joint. The MRI appearance of enthesitis is quite 
distinctive characterised be marked inflammation in adjacent bone marrow and soft tissues 
(McGonagle, Gibbon et al. 1998). In PsA, MRI has detected enthesitis in clinically 
uninvolved joints suggesting that enthesitis may be the primary lesion in PsA. This is 
supported by the observation that enthesial inflammation may extend as far as the synovial 
cavity. MRI assessment o f PsA hand disease has demonstrated 2 distinct patterns- synovial 
inflammation alone or capsular inflammation with synovitis (Jevtic, Watt et al. 1995). This 
suggests that PsA hand disease has either an enthesitis-related pathology or one identical to 
RA. Although differentiation between enthesial and synovial inflammation can be difficult 
in small joints due to the close proximity o f the 2 lesions, fat suppressed MRI is capable of 
identifying bone oedema at the capsule insertion characteristic o f enthesitis (Me Gonagle, 
Gibbon et al. 1999). The bone enthesis interface is an area o f increased vascularity 
rendering it susceptible to bacterial colonisation. This may offer a plausible explanation for 
the clinical features o f enthesitis in reactive arthritis. Detailed evaluation of the enthesis 
from humans with seronegative arthritis may provide insights into the link between 
infection and arthiitis and HLA responses to native antigens (McGonagle, Conaghan et al.
1999).
Ultrasound has also been usefully employed in musculoskeletal medicine since the 1970s 
(Cooperberg, Tsang et al. 1978). Its technology relies on echoes from pulsed sound waves 
to provide data for the generation o f images. Real-time sonography provides a 
continuously updated or "live" image while the patient is being scanned. The higher the 
frequency o f ultrasound, the sharper the resolution of the image and greater or lesser depth 
of tissue evaluated. Frequency is determined predominantly by the choice of the probe.
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also known as the transducer. High-frequency probes (7.5 to 10 MHz) are used for 
scanning tissue close to the surface such as tendons and small joints. Low-frequency 
probes (3.5 to 5 MHz) are used to scan deep internal structures such as the hip. Ultrasound 
is being increasingly used as a diagnostic tool and injection aid to rheumatologists. In PsA, 
it has proven efficacy in the detection and treatment of small joint synovitis (Grassi, 
Lamanna et al. 1999) and Achilles’ tendonitis (Balint and Sturrock 2000). Ultrasound also 
defines joint and enthesial involvement that is superior to clinical examination (Kane, 
Greaney et al. 1999).
29
Non pustular psoriasis Pustular psoriasis
Type 1 early onset Generalised
Type II late onset Von Zumbusch
Guttate Impetigo heipetiformis
Psoriatic erythroderma Localised
Dmg induced psoriasis Palmo plantar pustular psoriasis 
Acrodermatitis continua 
Amiular pustular psoriasis
Table 1.1 Clinical forms of pustular and non-pustular psoriasis.
The various forms o f psoriasis described are broadly divided in to the pustular and non- 
pustular varieties. There is some overlap between categories and like articular disease, 
clinical phenotype may vary over time.
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1.2 Current treatment in PsA
The use o f disease modifying anti rheumatic drugs (DMARDs) for PsA has been less well 
studied than in other inflammatory aithritides such as RA. The problems o f diagnostic 
criteria, different disease subsets and the marked placebo effect in this group have hindered 
therapeutic trials. Furthermore, outcome measures had until recently not been standardised 
to allow monitoring o f therapeutic efficacy. To address this, the PsA response criterion 
(PsARC) was developed (Clegg, Reda et al. 1996). This is a composite score requiring 
improvement o f two factors (one being joint score) and worsening o f none o f the 
following: patient and physician global assessments, tender and swollen joint scores. Prior 
to the PsARC, outcome measures in PsA clinical trials included a variety o f patient 
reported (early morning stiffness, night pain and patient global assessment), clinician, 
laboratory (ESR and CRP) and radiographic assessments (Clegg, Reda et al. 1996).
The currently available conventional therapies for PsA include sulphasalazine, 
methotrexate, cyclosporin, intramuscular gold and leflunomide. These therapies often 
induce disappointing clinical responses and can be associated with significant toxicity. 
Since 1964, there have been 12 randomised-controlled trials o f disease modifying agents in 
psoriatic artluitis involving 962 patients, 11 o f which have been analysed in a recent Meta 
analysis (Jones, Crotty et al. 1997) (see table 1.4).
Methotrexate
Intravenous methotrexate was first used to treat PsA in a double blind study o f 21 patients 
(Black 1964). Although the regime was effective, unacceptable toxicity precluded its use 
in this way. 20 years later, a trial o f oral methotrexate was conducted on 37 patients
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(Willkens, Williams et al. 1984). Although a significant improvement in physicians’ global 
assessment was detected, there was no effect on swollen joint counts. This study was 
significantly underpowered and hence interpretation is limited. Gold and methotrexate 
have been compared in a retrospective analysis of 87 PsA patients (Lacaille, Stein et al. 
2000). This study suggested that both agents are efficacious in PsA however methotrexate 
is superior to gold in terms o f clinical response and the ability to reduce concomitant 
steroid use. This study also suggests early use o f DMARDs results in better clinical 
response in PsA. Moreover gold is likely to be associated with higher toxicity (Hamilton, 
Mclnnes et al. 2001).
To address the efficacy and safety of methotrexate in PsA, the ARC/BSR/MRC Clinical 
Trials Collaberation has initiated a multicentre, placebo controlled trial o f methotrexate in 
Psoriatic Arthritis (MIPA), This study will test the hypothesis that therapy for 6 months 
with methotrexate will reduce articular and cutaneous disease and improve physical 
function in patients with active PsA.
Sulphasalazine
Six studies have been performed to examine the efficacy o f sulphasalazine in PsA. The two 
largest studies enrolled a total o f 487 subjects (Dougados, vam der Linden et al. 1995) 
(Clegg, Reda et al. 1996). Those on active treatment showed only just significant 
improvement over the placebo group in terms o f their composite indices however the 
placebo response was large at 44.6%. Another study revealed an improvement in pain 
scores but not joint count (Combe, Goupille et al. 1996).
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In a 1 year open study o f 34 patients taking sulphasalazine there was an overall favourable 
response in 67% of patients (Farr, Kitas et al. 1988). Similarly a 6-month placebo 
controlled study o f 39 patients suggested improvements in visual analogue score, early 
morning stiffness and articular index (Fraser, Hopkins et al. 1993). Another small study 
showed a significant improvement with sulphasalazine after only eight weeks treatment 
(Gupta, Grober et al. 1995).
Leflunomide
Leflunomide is a novel immunomodulatory drug that has been licensed for the treatment of 
active RA in several countries including the U.S.A. and Europe. The active metabolite of 
leflunomide, A l l  1726, inhibits proliferation o f activated T and B cells mainly through 
inliibition o f protein tyrosine kinases and the enzyme dihydroorotate dehydrogenase that is 
involved in the de novo synthesis o f pyrimidine nucleotides (Breedveld and Dayer 2000). 
Other in vitro activities o f A l l  1726 include the modulation of cytokine production in T 
cells and neutrophils, suppression o f immunoglobulin synthesis in B cells and reduction of 
MC adhesion, suggesting a therapeutic potential in a broad range of inflammatory and 
autoimmune disorders. There has been one report o f successful treatment with leflunomide 
in combination with prednisolone lOmg in a 56-year-old woman with a 44-year history of 
psoriasis vulgaris and a 15-year history o f PsA (Reich, Hummel et al. 2002). The role of 
leflunomide in PsA is not yet clear and controlled trials are ongoing.
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Penicillamine
Penicillamine has not been shown to be o f benefit in PsA. However the one study 
performed only enrolled 11 patients therefore interpretation is limited (Price and Gibson 
1986).
Gold (Auranofin)
A study o f 238 patients on intramuscular gold showed a small but significant benefit in the 
physician’s global assessment (Carette, Calin et al. 1989). A further study comparing 
auranofin and intramuscular gold to placebo em'olled 82 o f which only 51 patients 
completed the study (Palit, Hill et al. 1990). Only intramuscular gold improved pain score, 
Ritchie articular index (RAI) and ESR.
Other agents
There is as yet no evidence for the use of azathioprine, hydroxyurea, mycophenolate 
mofetil or cyclosporin in the treatment o f PsA.
Summary
Toxicity and sub optimal efficacy limit currently available conventional therapies in PsA. 
Clearly there is umnet need that requires to be addressed. Many o f the conventional 
therapies employed thus far in PsA have poorly characterised modes o f action and are used 
based mainly on their clinieal efficacy in RA. Their less convincing efficacy in PsA 
suggests discrete pathogenesis requires to be understood if  new therapies are to emerge for 
PsA. The beneficial effects emerging from anti TNF therapies in PsA and psoriasis indicate
36
that elucidation o f the pro inflammatory pathways may yield further therapeutic targets. 
This provides powerful rationale for the studies contained in this thesis.
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1.3 The role of arthroscopy in synovial biology
Insights into synovial biology have advanced rapidly since the introduction o f synovial 
biopsy techniques. Early research using a blind needle biopsy approach provided 
conflicting results due to inter observer variation. For this reason the European Synovitis 
Study Group (ESSG) was formed at the European League Against Rheumatism (EULAR) 
meeting in Amsterdam in 1995. Specifically their aims were to provide guidelines for 
training, to develop protocols for tissue selection and preparation and to standardise 
methods for quantification of immunohistological and pathological features o f synovial 
inflammation. The group is answerable to EULAR and has collaborations with North 
America and Australia. The synovial response to various DMARDs is emerging as a 
method of quantifying response to treatment and as such may become a more popular tool 
amongst rheumatologists in the future (Bresnihan, Tak et al. 2000),
Synovial tissue can be obtained by 2 methods: blind needle biopsy from the suprapatellar 
pouch or under direct vision using a needle arthroscope. Although the latter is more 
expensive and time consuming, it has the advantage of providing larger samples for tissue 
analysis. In addition the tissue provides a better representation o f the overall synovium as 5 
separate biopsies are processed as a single block. It also allows complete irrigation o f the 
joint cavity prior to steroid injection, which may result in greater efficacy (Weitoft and 
Uddenfeldt 2000). Finally blind needle biopsy tends to underestimate the intensity of 
macrophage infiltration in areas adjacent to cartilage (Youssef, Kraan et al. 1998) whereas 
needle arthroscopy allows direct visualisation of the cartilage parmus junction (CPJ).
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1.4 Immunopathogenesîs of PsA and psoriasis
1.4.1 Normal synovium
The normal SM is a discrete organ with its own circulation, lymphatic system and 
imiervation. It contains a lining layer of up to 3 cells thickness consisting o f macrophages 
and fibroblasts measuring 25-35 p,m in depth. Superficial type A synoviocytes are CD68^ 
and non-specific esterase (NSE) positive bone m anow  derived cells o f the 
monocyte/macrophage lineage. Type B synoviocytes are of fibroblast origin, derived from 
local proliferation of adjacent underlying stromal cells. Type B cells form a loose boundary 
between lining layer and deeper highly vascular fibrous connective tissue that contains few 
cells. The absence o f a basement membrane allows traffic of nutrients and waste products 
between plasma and SF. Although there is evidenee o f MHC class II expression in the 
lining layer and deeper macrophage like cells, there is little evidence o f ongoing 
inflammation in the normal synovium.
1.4.2 SM in PsA
In contrast, PsA synovium is characterised by a sub lining layer MC infiltration with 
predominantly CD4VCD45RO’^ and CD8^/CD45R0^ T cells. The lining layer is thin 
compared with RA but still consists o f 4-6-cell depth. Increased vascularity is observed 
with a reduction in E-selectin expression (Veale, Yanni et al. 1993). Such differences in 
histopathologic features are associated with variation in cytokine expression such as IL-2
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(Wong, Howell et al. 1996) (Howell, Warren et al. 1991) suggesting fundamental 
differences in the pathogenesis of seronegative arthropathies.
Further differences between the macroscopic vascular appearances o f PsA SM compared 
with RA have been described. In PsA SM, blood vessels appear tortuous and bushy vessels 
whereas RA SM has mainly straight, branching vessels (Reece, Canete et al. 1999).
1.4.3 Cutaneous changes in psoriasis
Histologically, established psoriatic lesions demonstrate marked epidermal hyperplasia, 
parakeratotie scale, and microabscesses (Munro microabscesses) of neutrophils within the 
superficial epidermal layers (Ebling 1999). An early cellular event in the development of 
psoriatic lesions is the infiltration o f target sites by activated memory T cells, neutrophils, 
macrophages and dendritic cells. This cellular infiltration in turn produces inflammatory 
mediators, such as IFNy that can induce epidermal hyperplasia, and may aet with 
kératinocytes and dermal macrophages to sustain a cycle o f inflammation that finally leads 
to the psoriatic phenotype.
The beneficial effects of CTLA4 Ig that binds to and blocks CD28 support a probable role 
for CO stimulation in psoriasis pathogenesis. In 43 patients who received 4 infusions o f the 
soluble chimera protein CTLA4Ig (BMS-188667) 46% achieved a 50% or greater 
sustained improvement in clinical disease activity with progressively greater effects in the 
highest-dosing cohorts. Improvement was associated with quantitative reduction in 
epidermal hyperplasia, which correlated with quantitative reduction in skin-infiltrating T
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ceils. No markedly increased rate o f intraleslonal T-cell apoptosis was identified, 
suggesting that the decreased number of lesional T cells was probably attributable to an 
inhibition o f T-cell proliferation, T-cell recruitment, and/or apoptosis o f antigen-specific T 
cells at extralesional sites (Abrams, Lebwohl et al. 1999) (Abrams, Kelley et al. 2000).
The temporal relationship o f streptococcal infection and guttate psoriasis has led some 
investigators to examine the role o f infection in pathogenesis (Henderson and Highet 
1988). This association has generated interest in the possible role o f Toll-like receptors 
(TLR) that identify microbial antigens as a first line o f defence by the innate immune 
system and as such may trigger the initial event in an abnormal immune response.
1.4.4 Involvement of T lymphocytes in PsA and psoriasis
Whereas T lymphocytes lie central to the regulation o f the normal immune response, 
dysregulation o f T cell may lead to disease pathogenesis. The majority o f rheumatoid 
synovial T cells are o f CD4^ helper subset found in perivascular aggregates that 
occasionally contain germinal centres. CD8^ cells are found in the transitional zone 
surrounding aggregates or scattered throughout the interstitium. Synovial T cells are 
predominantly CD45R0^, CD45RA' indicating differentiation within the memory subset. 
They express activation markers such as MHC class II particularly HLA-DR4 and several 
adhesion molecules including ICAM-1, together with integrins VLA-1, VLA-4 and LFA-1 
Only a small number o f synovial T cells are in cell cycle (Bonvoisin, Cordier et al. 1984). 
The accumulation of synovial T cells is likely to represent preferential migration of 
memory T cell into the inflamed synovium.
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Evidence from several sources strongly indicates psoriasis and PsA are T cell mediated
diseases.
• In psoriasis T cell activation and T cell receptor repertoire skewing are demonstrated in 
skin (Nikaein, Morris et al. 1993).
• In PsA, the SM contains large populations o f activated memory T cells (CD4 and CDS 
compartments). These lymphocyte populations demonstrate a predominance o f CD8^ 
lymphocytes with restricted T cell Vp gene expansions suggesting a specific response 
to a particular antigen (Costello, Winchester et al. 2001). (Braathen, Fyrand et al. 
1979). Moreover some similarities with recognition by cutaneous T cells o f the same 
epitope exists in studies in which T cell populations in skin and joint have been 
compared in the same patients (Tassiulas, Duncan et al. 1999).
• Langerhans cells isolated from psoriatic epidenmis are potent APCs and weak antigen 
processing cells (Baadsgaard, Gupta et al. 1989). Such Langerhans cells have been 
shown to induce T lymphocytes to produce a range o f cytokines that modulate 
cutaneous inflammation.
• T cell directed therapies have been shown to be o f limited benefit in the treatment of 
psoriasis (Ortonne 1996)
• Alefacept, a fully human lymphocyte-function associated antigen 3 (LFA-3/IgG fusion 
protein that blocks CD2/LFA-3 interaction has beneficial effects in PsA. Treatment for 
12 weeks resulted in a significant decrease in DAS associated with a reduction in 
synovial T cell/ macrophage infiltration in serial biopsies (Kraan, van Kuijk et al. 
2002). Modified anti-CD3 therapy in PsA has reached phase II clinical trials with 75% 
improvement in swollen joint counts in 6 of 7 patients after 1 month o f treatment 
(Utset, Auger et al. 2002). These data further support that T cell activation plays an
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important role in pathogenesis o f PsA. Benefits have also been observed in clinical 
trials in psoriasis (da Silva, Brickelmaier et al. 2002).
Blockade of CTLA-4 (cytotoxic T lymphocyte-associated antigen-4 or CTLA-4), 
expressed on activated T cells reverses the cellular pathology of psoriatic plaques, 
including the activation o f kératinocytes, dendritic cells, and endothelial cells (Abrams, 
Kelley et al. 2000).
1.4.5 Functional T cell subsets
Almost 30 years ago, functional heterogeneity in CD4"  ^ cells was recognised (Liew and 
Parish 1974). Subsequently Thl and Th2 type T cells were classified based on their 
cytokine production (Mosmann, Cherwinski et al. 1986). Whereas T hl cells secrete IL-1, 
IFNy IL-17and TNFp, Th2 cells secrete IL-4, IL-5, IL-10 and IL-13. Thl responses are 
efficient in eliminating intracellular pathogens via macrophage activation. Th2 responses 
effect humoral immune responses to persistent antigen. Most immune responses involve 
contributions from both Thl and Th2 cells that cross regulate each other’s effector 
functions. Thus a balance between Thl and Th2 cytokines can determine whether the 
immune response is appropriate or will result in detrimental immunopathogenesîs. 
Overproduction o f Thl cytokines has been implicated in delayed type hypersensitivity 
reactions and autoimmune diseases whereas Th2 cytokines recruit eosinophils and mast 
cells leading to allergic and inflammatory conditions (Romagnani 1994).
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The differentiation o f Thl and Th2 responses from precursor Th cells (Thp) depends on a 
variety o f complex developmental processes. The dose o f antigen, density of the antigen 
peptide: MHC complex and co stimulation all influence the initiation of Th differentiation. 
Recent data suggest vasoactive intestinal peptide may drive Th2 responses (Delgado 2003). 
The observation that naive antigen activated Thp could be induced to differentiate into Thl 
or Th2 lineage in vitro by the addition of exogenous cytokine was an important 
development in understanding the regulation o f Thl/Th2 responses. Cytokines (TNFa, IL- 
1, IL-4, IL-6, IL-12 IL-18 and IFNy) play central roles in initiating and regulating the 
overall immune system. These cytokines are not only involved in regulating the innate 
immune system but are also critical to the development and propagation of acquired 
immune responses. The overlap in functions of many cytokines underscores the close 
relationship between innate and acquired immunity.
The ability of a Th cell to respond to both autocrine and exogenous cytokines depends on 
their ability to regulate expression of certain receptors e.g. IL-4 directly down regulates IL- 
12 receptors whereas IL-12 produced by APCs results in a positive feedback loop o f IFNy 
production that subsequently down regulates IL-4 receptor expression. In the absence o f 
IL-12, IL-4 rapidly down regulates IL-12 receptors an effect amplified by IL-10. Thus Th2 
cytokines seiwe a default pathway with Thl responses depending on sufficient 
concentrations o f IL-12 and IFNy to combat IL-4 and ILIO.
Transcriptional factors that regulate cytokine gene expression have also been elucidated. 
IL-12 via Stat-4 activation induces transcription factor T-bet whereas IL-4 via Stat-6 
activation induces GATA-3. The expression o f GATA-3 and T-bet during Thl and Tli2 
differentiation is mutually exclusive (Rengarajan, Szabo et al. 2000). Subsequent studies
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are investigating the consequences o f such exclusivity since this offers an obvious 
therapeutic intervention for specific arms o f the acquired T cell response.
The relative expression o f Thl/Tli2 cytokines has been employed to determine the 
predominant Th response in disease states. One o f the difficulties in identifying a Thl 
response via IFNy detection is the low number o f spontaneous IFNy producing cells that 
may be directly visualised in inflammatory lesions. Consequently, functional polarity is 
usually inferred from relative expression of cytokine mRNA within lesions, or by 
quantification at the protein level of IFNy / IL-4 / IL-5 ratios after mitogen stimulation. 
The ability to phenotype Th responses has been considerably advanced by the discovery of 
markers capable of identifying respective subsets. Thl cells express CCR5 (Loetscher, 
Uguccioni et al. 1998), IL18R (Xu, Chan et al. 1998), and IL-12(32 whereas Th2 cells 
express predominantly CCR3, CCR8 and ST2L (Xu, Chan et al. 1998). Although 
expression o f these markers is transient, their existence lends credence to the Thl/Th2 
dichotomy in the human immune system. It is possible to critically evaluate the 
contribution of Thl and Th2 cells in human disease states using these specific cells surface 
markers and the identification of IL-18R on RA synovial T cells indicates the utility o f this 
approach ex vivo (Xu, Chan et al. 1998).
The foregoing is now o f fundamental importance in evaluating disease state pathogenesis. 
The elucidation o f phenotype and regulation of Th response in disease states such as 
psoriasis and PsA may offer therapeutic intervention. Manipulation of the T hl response via 
the administration o f cytokines o f reciprocal activity such as IL-10 is clinically beneficial 
in both articular and cutaneous disease (Mclnnes, Illei et al. 2001). Furthermore, the
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beneficial effects of fumarates in psoriasis are achieved via downregulation of 
IFNy expression by circulating blood cells (Litjens, Nibbering et al. 2003).
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1.4.6 Fibroblasts
The normal synovium contains mesoderm fibroblasts also known as type B lining cells. 
Fibroblast like synoviocytes (FLS) are prominent in the proliferating synovium during 
chronic synovitis. These cells are a source o f proinflammatory cytokines and growth 
factors thus contributing to the inflammatory process within the synovium. In contrast to 
dermal fibroblast cultures from normal skin, synovial fibroblasts are capable o f providing 
CO stimulatory activity for activation o f resting T cells (Looney, Hooper et al. 1995). 
Psoriatic fibroblasts, cultured from involved skin and synovium exhibit a greater 
proliferative response to growth factors compared to normal fibroblast (Espinoza, Aguilar 
et al. 1994) and as such may be key players in the inflammatory response. Indeed RA 
synovial fibroblast expression o f IL-18 has previously been described and such expression 
is up regulated by TN F-a and IL -lp  (Grade, Forsey et al. 1999). Furthermore the ability 
o f synovial-derived fibroblasts to secret IL-6 and MMPs in response to cytokine 
stimulation such as IL-17 may elucidate a mechanism for cartilage damage in PsA.
48
1.4.7 Cytokine production in PsA and psoriasis
Large numbers o f cytokines involved in regulating the acquired immune system are 
necessary to obtain a fine level o f control to meet the immunological needs of the host to 
respond to a variety o f external pathogens.
TNFa
The identification o f TN Fa as a key molecule in the proinflammatory cascade has resulted 
in a better understanding o f how dysregulation o f the immune system leads to synovial 
inflammation. Lesional and systemic elevated levels of TN Fa have been found in psoriasis 
patients with and without artluitis. Furthermore, increased levels of TN Fa are found in the 
PsA SF compared with OA but less than RA (Partsch, Steiner et al. 1997).
Clinical trials employing anti TN Fa have resulted in clinical benefits in both psoriasis and 
PsA. Humanised anti TN Fa monoclonal antibody (infliximab) was used initially in a 
psoriatic patient who was suffering also from an inflammatory bowel disease. A dramatic 
improvement in skin lesions was observed two weeks after a single infusion (Oh, Das et al. 
2000). Good activity has also been reported in combination with methotrexate (Kirby, 
Marsland et al. 2001). Recently, the efficacy and safety o f infliximab monotherapy has 
been demonstrated in a controlled randomised trial. 33 patients with moderate to severe 
plaque psoriasis received a placebo or the monoclonal antibody at two dosages 
intravenously at weeks zero, two and six. 82% o f patients in the 5 mg /kg group and 73% 
in the 10 mg/kg group had at least a 75% improvement in PAST score. The mean PASI 
decreased from 22.1 to 3.8 (5 mg /kg) and 26.6 to 5.9 (10 mg/ kg) by week ten. The mean 
time to response was four weeks (Chaudhari, Romano et al. 2001).
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Similar efficacy and safety data on TN Fa targeted therapies are available for PsA (Mease 
2002). 60 patients were assessed in a randomised double blind placebo controlled trial of 
etanercept. Over the 12-week study, 87% of the etanercept treated group met the response 
criteria (PsARC) compared with 23% in the placebo group. In addition, the severity of 
psoriasis as measured using the PASI, improved by 46% in the treatment group compared 
with 9% in the placebo group. There were approximately 30% non-responders in this 
group (Mease, Goffe et al. 2000).
There have been additional reports o f success with anti TN Fa therapy in 
spondyloarthropathies (Brandt, Haibel et al. 2002). An open labelled study included 21 
treatment resistant patients with various subtypes of spondyloarthropathy 9 of whom had 
PsA. They received 3 infusions o f 5mg/kg infliximab at 0, 2 and 6 weeks. Although 
concomitant NSAIDs and corticosteroids were allowed, other DMARDs were discontinued 
4 weeks prior to the study. Rapid and significant improvements were noted throughout the 
treatment period and were maintained for up to 6 weeks following the last infusion (Van 
den Bosch, Baeten et al. 2001).
The FDA in USA has approved etanercept in PsA however UK approval is awaited. The 
identification o f other regulatory factors in the pro inflammatory cascade may therefore 
offer therapeutic potential.
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Interferon y
In contrast to easily detectable macrophage derived cytokine, T cell derived cytokine has 
been more difficult to elucidate. Significantly elevated expression o f IFNy was 
demonstrated in only 2 out o f 10 PsA patients (Partsch, Wagner et al. 1998). This is in 
contrast to other reports o f cytokine production and inRNA expression in synovium in PsA 
compared with RA and OA (Ritchlin, Haas-Smith et al. 1998). However, the issue 
regarding the role o f IFNy in PsA remains controversial. One study indicated that Thl 
response was of less magnitude in seronegative arthropathies than in RA (Canete, Martinez 
et al. 2000).
Although interferons (IFN) were initially described on the basis o f their antiviral activity, 
these cytokines have profound effects on the immune system. IFNs can be divided into two 
broad categories. Numerous IFNs exist varying on the basis of their cell o f origin, structure 
and functional effects. There are more than 30 subtypes of Type I IFNs (a  and (5) that 
virally infected cells secrete. In contrast to a  and p interferons, there is only a single type 
o f type II interferon (IFNy) that is produced by Thl effector cells in response to immune 
stimuli and by NK cells in response to IL-12. IFNy was first identified in 1966 (Wheelock 
1966). It is a polypeptide composed of 166 amino acids including a signal sequence that is 
cleaved to form a biologically active 143 amino acid sequence that forms a 34kD 
homodimer.
IFNy interacts with a specific receptor composed of 2 chains. The a  chain is a 90kD 
binding chain and the p chain is a 314 amino acid signalling chain. Each chain signals 
tlirough Janus kinase (JAK) - a  through JAK l and p through JAK2. IFNy initially binds to 
2 a  chains that dimerise resulting in transphosphorylation and reciprocal activation o f the 
JAKs. The activated JAKs then phosphorylate the tyrosine residues on the a  chains which
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in turn activates signal transduction and translation proteins (STATs). STAT homodimers 
than translocate to the nucleus where they bind to DNA sequences encoding gamma 
activated sequences (GAS).
IFNy plays an important role in T helper cell development. ÏL-18 (interferon-inducing 
factor) and IL-12 exhibit a marked synergism in IFNy induction by T cells (Okamura, 
Kashiwamura et al. 1998).
IFNy protects the host against exogenous pathogens by maximising antigen presentation 
via up regulation o f co stimulatory molecules CD80 and CD86 on macrophages, T and B 
cells and dendritic cells.
T cells stimulated by IFNy activate macrophages to produce superoxide radicals such as 
hydrogen peroxide and nitric oxide that have antimicrobial and anti viral properties. This 
results in the non-specific eradication o f exogenous pathogens from the host.
As well as having a key role in regulating subsequent immune responses, IFNy has effects 
on bone remodelling. Bone remodelling is a dynamic process regulated by the opposing 
actions o f osteoclasts (bone resorption) and osteoblasts (bone formation). 
Osteoclastogenesis, the process o f bone resorption is enhanced by the RANK/RANKL 
(receptor activator of NFkB) interaction. It has been demonstrated that IFNy can inlribit 
osteoclastogenesis by inducing the rapid degradation o f the RANK adapter protein TRAF6 
(tumour necrosis factor receptor associated factor 6) (Takayanagi, Ogasawara et al. 2000). 
Therefore diseases in which IFNy is over expressed may exhibit features o f new bone 
formation.
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Between 1988 and 1998, IFNy was administered to more than 2000 patients with either RA 
or juvenile RA. Most were double blind placebo controlled studies. The rationale for 
using IFNy as a therapy in RA was based on pre clinical trials in which IFNy antagonised 
the effects of IL-1 on monocytes, chondrocytes and synovial cells including inhibiting 
PGE2, IL -lp  and collagenase production. In addition IFNy inhibited IL-15 induced IL-8 
from human monocytes. Although 1-year data suggested an improvement in disease 
activity indices with reduction in corticosteroid requirements (Sprekeler, Lemmel et al. 
1990), 5-year follow up data revealed that 67% of patients had withdrawn from treatment 
due to lack o f efficacy with only 11% remaining on therapy (Lemmel, Gaus et al. 1991). 
IFNy has also been employed as a treatment for PsA (Fierlbeck and Rassner 1986). In this 
study, 10 of 15 patients treated with subcutaneous recombinant IFNy had relief of joint 
pain within 28 days. However no further improvement was observed after the third month, 
and patients classified as responders in the first month showed a deterioration of the 
disease with continuing treatment (Fierlbeck and Rassner 1990). Furthermore, in 10 of 42 
patients, psoriatic lesions developed at the injection site (Fierlbeck, Rassner et al. 1990).
Interleukin 18
Interleukin-18 (IL-18), a member o f the interleukin-1 cytokine superfamily, is now 
recognised as an important regulator of both innate and acquired immune responses. IL-18 
is expressed at sites o f chronic inflammation, in autoimmune diseases, in a variety of 
cancers and in the context o f numerous infectious diseases.
IL-18, previously known as IFN-y Inducing Factor (IGIF), was identified as an endotoxin- 
induced serum factor that stimulated IFN-y production by murine splenocytes (Nakamura,
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Okamura et al. 1989). IL-18 was cloned from a murine liver cell cDNA library generated 
from animals primed with heat-killed Propionibacterium acnes and subsequently 
challenged with LPS (Okamura, Tsutsi et al. 1995). Nucleotide sequencing o f murine IL- 
18 predicted a precursor polypeptide o f 192 amino acids lacking a conventional signal 
peptide, and a mature protein o f 157 amino acids. Subsequent cloning of human IL-18 
cDNA revealed 65% homology with murine IL-18 (Ushio, Namba et al. 1996) and showed 
that both contain an unusual leader sequence consisting of 35 amino acids at their N- 
terminus.
IL-18 expression has been reported in macrophages, dendritic cells (DC), Kupffer cells, 
kératinocytes, osteoblasts, adrenal cortex cells, intestinal epithelial cells, microglial cells 
and synovial fibroblasts. IL-18, like IL-1 (3 with which it shares structural homology, is 
produced as a 24 kD inactive precursor lacking a signal peptide (pro-IL-18). Pro-IL-18 is 
cleaved after Asp35 by the endoprotease IL -lp  converting enzyme (ICE, caspase-1) to 
generate a biologically active mature 18 kD moiety (Gu, Kuida et al. 1997) (Ghayur, 
Baneijee et al. 1997).
Like that o f IL-1, the IL-18R complex is a heterodimer containing an a  (IL-lRrp) chain 
responsible for extracellular binding o f IL-18 and a non-binding, signal transducing p 
(AcPL) chain (Torigoe, Ushio et al. 1997) (Hoshino, Tsutsui et al. 1999). Both chains are 
required for functional IL-18 signalling (Born, Morrison et al. 2000). IL-18R is expressed 
on a variety of cells including macrophages, neutrophils, NK cells, endothelial and smooth 
muscle cells (Hyodo, Matsui et al. 1999; Leung, Culshaw et al. 2001; Afkarian, Sedy et al. 
2002). The IL-18R complex can be upregulated on naïve T cells, Thl type cells and B cells 
by IL-12 (Hoshino, Tsutsui et al. 1999) (Yoshimoto, Takeda et al. 1998). IL-18Ra 
retention on the membrane o f mature Thl cells serves as a marker for the latter in humans
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and murine systems (Xu, Chan et al. 1998). In contrast, T cell reeeptor (TCR) ligation in 
the presence o f IL-4 results in downregulation o f the IL-18R (Smeltz, Chen et al. 2002). 
Modulation o f this complex is therefore likely to be functionally significant. Consistent 
with this, administration o f anti-IL-18R a antibody in vivo results in reduced LPS induced 
mortality associated with a subsequent shift in balance from a Thl to a Th2 immune 
response (Xu, Chan et al. 1998).
Although originally identified as a factor capable o f inducing IFN-y production by murine 
splenocytes, the effector role of IL-18 is rapidly expanding. Consistent effects on lymphoid 
series, particularly Thl lineage in combination with IL-12 have emerged (Okamura, Tsutsi 
et al. 1995). Thus IL-18 enhances T and NK cell maturation, cytokine production and 
cytotoxicity (Okamura, Tsutsi et al. 1995) (Yoshimoto, Takeda et al. 1998) (Micallef, 
Ohtsuki et al. 1996) (Dao, Mehal et al. 1998). IL-18 also increases FasL on NK cells and 
consequent Fas-FasL-mediated cytotoxicity (Dao, Ohashi et al. 1996) (Tsutsui, Nakanishi 
et al. 1996). IL-18 deficient mice have reduced NK cell cytolytic ability that can be 
restored by exogenous IL-18 (Takeda, Tsutsui et al. 1998). However, together with IL-2, 
IL-18 coinduces IL-13 in murine T and NK cells and in the presence of TCR activation 
induces T cell IL-4, IL-10, IL-13 and IFN-y production (Hoshino, Wiltrout et al. 1999). In 
isolation IL-18 induces high IgE expression by B cells and in combination with IL-2, anti- 
CD3 and anti-CD28 markedly enhances IL-4 production by CD4^T cells (Yoshimoto, 
Mizutani et al. 2000). When cultured alone or in combination with IL-4, IL-18 is known to 
induce murine T cell Th2 differentiation. This however is dependent upon genetic 
influences as spleen cells from BALB/c and C56BL/6 strains o f mice stimulated with anti- 
CD3 and IL-18 exhibit entranced Th2 and Thl responses, respectively (Xu, Trajkovic et al.
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2000). Thus IL-18 can promote Thl or Th2 lineage maturation dependent upon underlying 
genetic influences and the ambient cytokine milieu.
Kératinocytes, traditionally thought to produce but not process IL-18 (Mee, Alam et al. 
2000), have now been shown to secrete biologically active IL-18 when treated with 
dinitrochlorobenzene and pro-inflammatory mediators such as LPS (Naik, Camion et al.
1999). In addition to kératinocytes, Langerhans cells (LC) also produce IL-18, which in 
turn contributes to the regulation of LC migration (Cumberbatch, Dearman et al. 2001).
IL-18 expression and effector function have now been described in inflammatory diseases 
across a broad range o f tissues. We have focussed on recent key examples of a pro- 
inflammatory role for IL-18.
Data from studies in RA clearly indicate that IL-18 and its receptor system are present in 
inflammatory synovitis (Gracie, Forsey et al. 1999) (Yamamura, Kawashima et al. 2001) 
(Tanaka, Harigai et al. 2001). Its functional activities include promotion o f cytokine 
release (particularly TN F-a, GM-CSF and IFN-y). Marked synergy with IL-12 and IL-15 
is observed in this respect. IL-18 acts not only through lymphocyte activation, but also 
tluough direct effects on macrophages. IL-18 expression is in turn upregulated in FLS by 
IL -ip  and TNF-a, suggesting the existence o f positive feedback loops linking monokine 
predominance in RA with imiate cytokine production and Thl cell activation in synovial 
immune responses. IL-18 induces NO release by RA SM in vitro that, since NO inhibits 
caspase-1 activity, provides a further potential regulatory loop. IL-18 possesses pro- 
degradative effects in articular cartilage. IL-18 reduces chondroeyte proliferation, 
upregulates iNOS, stromelysin and cycloxygenase 2 expression and increases 
glycosaminoglycan (GAG) release in vitro. Such activities may be IL -ip  independent 
although contradictory data have also emerged (Lubberts, Joosten et al. 2001). IL-18
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further promotes synovial chemokine synthesis and angiogenesis (Morel, Park et al. 2001) 
(Park, Morel et al. 2001). Finally, IL-18 effects are not necessarily detrimental. IL-18 
inhibits osteoclast maturation through GM-CSF production by T cells, thereby retarding 
bone erosion (Horwood, Udagawa et al. 1998). Suppression of COX expression may also 
be mediated tluough IFN-y production with consequent effects upon prostanoid mediated 
local inflammation.
The process whereby IL-18 and IL -lp  are released from the cytosol are unknown. Both 
molecules are regulated post transcriptionally, and a particularly important aspect of 
regulation oceurs at the level o f release.
In this context, recent studies show that this release pathway can be rapidly induced by 
stimulation with exogenous ATP. In macrophages, exogenous ATP works via the recently 
cloned P2X7 receptor, a member o f the P2X family o f nucleotide-gated channels that are 
activated by extra cellular ATP.
P2X7 is a 5 95-amino acid polypeptide with two membrane-spamiing domains and 
intracellular N- and C-terminal domains.
P2X7 receptor is the only pore-forming P2X family member, and its activation results in 
the opening o f a cationic channel with increased permeability to calcium and intracellular 
depolarisation.
Recent studies have shown that monocytes express functional P2X7 receptors that 
modulate IL la  and IL-18 processing and release in response to ATP (Mehta, Hart et al. 
2001).
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IL -18 has been targeted in several arthritis models in vivo. Upon challenge with type II 
collagen (CII) in CFA, IL-18-deficient mice on a DBA/1 background exhibit reduced 
incidence and severity o f arthritis. Ex vivo analysis determined that both cellular and 
humoral responses to CII were suppressed (Wei, Leung et al. 2001) (Leung, Mclnnes et al.
2000). Moreover, administration of recombinant IL-18 can replace the requirement for 
CFA in CII induced erosive arthritis in DBA/1 mice (Leung, Mclnnes et al. 2000). 
Neutralisation of IL-18 in vivo using specific antibodies or IL-18BP effectively reduces 
developing and established rodent arthritis in both streptococcal cell wall and CIA models 
(Lubberts, Joosten et al. 2001) (Plater-Zyberk, Joosten et al. 2001). Such effects may 
operate independent o f IFN-y (Lubberts, Joosten et al. 2001). A feature o f both models is 
suppression not only o f inflammation but also o f matrix destruetion. These data strongly 
suggest that the net effect o f IL-18 expression is pro-inflammatory, at least in the context 
o f antigen-driven articular inflammation. Clinical studies to test this hypothesis in RA are 
awaited.
The position o f IL-18 in the functional hierarchy o f pro-inflammatory cytokines in ehronic 
inflammation is not fully resolved, although there is consensus that it plays a critical early 
role. Nevertheless, IL-18 appears able to modulate inflammation at multiple check points, 
acting not only on initiation and expansion o f putative auto-reactive Thl responses but also 
via direct effects on multiple cellular targets, including macrophages, lymphocytes and 
target host tissue cells, including endothelial cells and fibroblasts. As such it may offer a 
therapeutic target for the treatment o f inflammatory disease states.
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Interleukin 12
IL-12 initially designated as natural killer cell stimulatory factor was originally identified 
as a product o f Epstein-Barr virus transformed lymphoblastoid B cell lines that mediate 
several biological activities on human T and NK cells including induction o f IFNy and 
enliancement of cell-mediated cytotoxicity (Kobayashi, Fitz et al. 1989).
It is a 70kD disulphide-linked heterodimer consisting of 35kD (p35) and 40kD (p40) sub 
units. Although p35 transcripts are found in many tissue types, the p40 subunit is only 
found in tissues that express the whole IL-12 p70 molecule. No biologic activity is 
observed with either sub unit alone however the p40 subunit can be synthesised in large 
amounts to act as a natural inhibitor o f IL-12.
IL-12 is predominantly produced by monocytes and macrophages but also by several other 
cell types including Langerhans cells, kératinocytes, dendritic cells and neutrophils 
(Trinchieri 1994).
Separate genes on separate chromosomes encode the two proteins and expression o f each 
is independently regulated. The structure of p35 is homologous to other cytokines whereas 
p40 is related to members o f the cytokine receptor super family.
The biologic activities o f IL-12 are mediated via specific high affinity receptors that are up 
regulated on T and NK cells following activation. One subunit of the IL-12 receptor 
complex was previously cloned and when expressed in COS cells bound IL-12 with low 
affinity. Because of its structural homology with the (3 subunit of the IL - 6  receptor it was 
termed IL12Rp. Shortly afterwards a second subunit o f the IL-12 receptor complex was 
cloned designated IL12R(32 and the previously identified subunit renamed IL12R(31. Co 
expression o f both receptors in COS cells resulted in the formation o f both high and low 
affinity binding sites (Presky, Gubler et al. 1995).
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Among the biologic activities o f IL-12 are its ability to promote the maturation o f Thl 
cells to produce IFNy by resting and activated T, NK and NKT cells. It also enhances the 
lytic activity and proliferation o f T cells and NK cells. Furthermore IL-12 is reported to 
act synergistically with IL-2 on activated B-Iymphocytes to enhance immunoglobulin 
secretion (Jelinek and Braaten 1995).
In collagen-induced artliritis, administration o f IL-12 accelerates disease onset and 
increases disease severity characterised by granulocyte influx increased expression of 
TN Fa and IL lp  mRNA (Joosten, Lubberts et al. 1997). In the same model, IL-12 deficient 
mice have less severe disease (Malfait, Butler et al. 1998).
In PsA, elevated levels o f IL-12 have been found in SF and serum in association with IL- 
13 (Spadaro, Rinaldi et al. 2002). In psoriasis increased protein expression in association 
with dendritic cells, macrophages and nerve endings has been described. (Turka, 
Goodman et al. 1995). Enhanced IL-12 p40 mRNA signals have been detected in lesional 
psoriatic skin as compared with normal and non lesional psoriatic skin. Furthermore, 
immunoreactivity for IL-12 p70 was markedly increased in the psoriatic skin lesions and 
was predominantly expressed on MCs in the dermis (Yawalkar, Karlen et al. 1998). 
Macrophage associated IL-12 expression has been described in RA and OA SM by 
immunohistochemistry (Sakkas, Johanson et al. 1998). However IL-12 p40 mRNA 
expression was increased in RA synovial tissues compared with OA (Morita, Yamamura et 
al. 1998).
The IFNy inducing properties o f IL-12 has led to its use in clinical trials in cancer and HIV 
to enhance tumoricidal activity o f NK cells and augment the T hl response respectively. 
Unfortunately toxicity was a major limiting factor requiring significant dose reduction.
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In contrast anti IL-12 would seem a reasonable treatment for conditions driven by Thl 
responses by limiting the production o f IFNy. Unfortunately therapies that limit IFNy 
production have had little impact thus far. Interestingly there is evidence that established 
DMARDs (auranofm and sulphasalazine) may exert their anti inflammatory effects 
through inliibiting IL-12 driven T hl mediated disease (Kim, Kang et al. 2001) (Hasko, 
Szabo et al. 2001) (Kang, Chung et al. 1999).
Interleukin 17
IL-17 was first identified as a rodent cDNA transcript, termed CTLA8 , isolated from an 
activated T-cell hybridoma (Yao, Fanslow et al. 1995). It has a leader peptide and is 
readily secreted from T cells. As in the case of IL-10, there is a viral homologue of IL-17, 
which is biologically active. Viral IL-17 is part o f the herpes virus-13 genome.
IL-17 is a T cell derived pro inflammatory cytokine stimulating a wide variety of cell 
types. From T cell clones established from RA synovium, virtually all ThO and Thl cells 
produce IL-17 whereas no Th2 clones produce IL-17 (Aarvak, Chabaud et al. 1999).
The receptor for IL-17 is unique in that the extracellular domains are not related to any of 
the known cytokine receptor families. The extracellular domains contain several cysteine 
residues that are not usually found in cytokine receptors. The IL-17 receptor is not a 
member of the immunoglobulin family o f receptors and is unique in possessing a long 
cytoplasmic domain. IL-17 receptor mRNA is present in nearly all cells.
IL-17, like other pro inflammatory cytokines, signals through NFkB and requires TRAF6 . 
As such, embryonic fibroblasts derived from TRAF6  deficient mice fail to induce 
expression of IL- 6  and ICAM-1 following stimulation with IL-17 despite the presence of
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IL -17 receptors comparable to those on wild type control cells (Schwandner, Yamaguchi et 
al. 2 0 0 0 ).
Although TN Fa inhibition has led to clinical benefits in terms of inflammation, the anti 
erosive effects have not been as marked. IL-1 is a pivotal cytokine in cartilage destruction 
via the potent induction o f MMPs by synovial fibroblasts. The pattern of cellular responses 
induced by IL-17 is similar to those o f IL-1. Indeed the addition o f IL-1 with IL-17 to 
human fibroblast cultures results in synergistic enhancement o f IL-6 , IL- 8  and PGE2 
production (Chabaud, Fossiez et al. 1998). Furthermore, IL-17 stimulates the production of 
IL-1 [3 and TN Fa by macrophages. In the collagen induced arthritis model, blocking IL-17 
results in suppression o f arthritis. In contrast over expression of IL-17 enhanced collagen 
arthritis. The cartilage destructive effects o f IL-17 appear to function independently of IL- 
1(3 as blocking IL-1 with neutralising peptide had no effect on IL-17 induced cartilage 
damage (Lubberts, Joosten et al. 2001).
IL-17 exerts its osteoclastogenic effects via NFkB dependant mechanisms. Activation of 
NFkB requires the interaction o f RANK/RANKL pathway that is dependent on the 
presence of TRAF6 . It has been shown that whereas IL-I7 induces TRAF6  expression, 
IFNy inhibits TRAF6 . Therefore inliibition and activation o f bone resorption may be 
occuning in the same joint depending on the predominant cytokine milieu. This may give a 
plausible explanation as to some o f the radiological features that are specific to PsA.
IL-17 has a variety o f biological activities including induction of chemokine synthesis and 
stimulation of inducible nitric oxide synthase (iNOS) and prostaglandin E2 (PGE2).
It has been shown to be present in the synovium and SF o f patients with RA (Chabaud, 
Durand et al. 1999). Furthermore, the majority of the CD4+ and CD8 + T cell clones 
derived from lesional psoriatic skin expressed IL-17 mRNA, suggesting that skin-
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infiltrating T cells can produce this cytokine. IL-17 mRNA is detectable in biopsies from 
lesional psoriatic skin, but not in non lesional control biopsies suggesting that IL-17 could 
amplify the development of cutaneous inflammation and may support the maintenance of 
psoriasis through stimulation o f kératinocytes to augment their secretion of 
proinflammatory cytokines (Teunissen, Koomen et al. 1998). The presence and role of IL- 
17 in PsA has not previously been studied.
IL-17 is similarly upregulated in lesional psoriatic skin, suggesting that it may play a role 
in the amplification and/or development of cutaneous inflammation. It may contribute to 
the recruitment o f T cells into the epidermis by inducing expression by primary 
kératinocytes of the chemokine CCL20 (Homey, Dieu-Nosjean et al. 2000).
Other cytokines and chemokines - Further work has been performed comparing monocyte- 
derived cytokines such as IL-15 in PsA and RA SM (Danning, Illei et al. 2000). IHC 
demonstrated the presence of IL-15 in both the RA and PsA synovium and the presence of 
NFkB indicates that such cytokines are o f functional significance.
The preferential expression o f IL- 8  and IL- 8  mRNA in psoriatic synovium indicate that 
chemokines may regulate leucocyte traffic into the SM (Konig, Krerm et al. 1996).
Summary
The discovery o f novel cytokines and associated natural inhibitory binding proteins has 
increased our understanding o f pro inflammatory pathways and as such has given us 
deeper insights into inflammatory disease pathogenesis. Furthermore, the ability to inhibit 
such cytokines has led to the development o f novel therapies in those diseases in which 
such cytokines have been shown to have functional significance.
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1.4.8 MAP kinase signalling pathways
Inflammatory mediators activate numerous intracellular signalling cascades resulting in 
transcription o f chemokines and pro inflammatory cytokines. These intracellular 
signalling cascades include the mitogen-activated protein kinase signal transduction 
pathways, which include the p38 mitogen-activated protein kinase (p38 MAPK) and the 
c-Jun N-terminal kinase. p38 MAP kinase inhibition has profound anti-inflammatory 
effects when administered to cells prior to stressful stimuli. Moreover, oral p38 MAP 
kinase inhibitors reduce TN Fa production by LPS injected mice by 91% (Wadsworth, 
Cavender et al. 1999). In animal models o f arthritis, prophylactic treatment with MAP 
kinase inliibitor reduced joint swelling and erosion. Furthermore, administration following 
onset o f arthritis arrested subsequent disease progression (Jackson, Bolognese et al. 1998). 
Recent in vivo data have implicated p38 MAP kinase pathway in Borrelia burgdorferia 
elicited inflammation with specific inhibitors repressing spirochete production of TN Fa 
(Anguita, Samanta et al. 1997). Although there are 4 isoforms of MAP kinase, the a  
isoform has been identified as a potential target for anti cytokine therapy. 
p38 MAP kinase is also involved in IL-18 and IL-12 induced T cell interaction with extra 
cellular matrix ligands (Ariel, Novick et al. 2002).
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1.5 The role of NK and NKT cells in immune regulation
1.5.1 Natural Killer (NK)
NK cells were first described in 1976 in mice due to their tumour lysing ability leading to 
profound interest in their potential treatment of malignancy (Kiessling, Petranyi et al. 
1976). These granular lymphocytes lack B and T cell surface markers and are characterised 
by an ability to secrete both T hl and Th2 cytokines depending on their cytokine milieau. 
Whereas IL-12 stimulates NK cell production of IFNy, IL-4 stimulates NK cell production 
o f IL-5, IL-10 and IL-13. This suggests that like T cells, NK cells can differentiate into 
discrete functional subsets with differing effects on adaptive immunity. Because o f their 
role in regulating the normal immune response, NK cells may also be important in auto 
immunity.
1.5.2 Natural Killer T (NKT) cells
A subset of T cells that express NK receptors are termed NK T cells. They were first 
described in 1987. NKT cells are distributed thioughout the body but are found mainly in 
the thymus where they represent 10-20% of mature T cells, liver (30-50%) and bone 
marrow (20-30%). They are different from NK cells in terms o f development, antigen 
recognition and function. These cells are characterised by the presence o f a T cell receptor 
made up o f two subunits -Va24 and V|311. The cells express the TCR/CD3complex and 
are activated through the TCR. NKT cells recognise glycolipid antigen when presented by 
the APC in association with the MHC class 1 like molecule CD Id. The crystalline
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structure o f CD Id differs from MHC molecule by having a large non-polar antigen-binding 
groove that allows it to bind the lipid moiety o f certain glycolipids In addition CD Id is 
encoded on chromosome 1 whereas HLA class 1 is encoded on clrromosome 6 .
NKT cells have eell surface markers CD56 and CD161 (NKR-PIA). There is however a 
variety o f cells within this subset resulting in functional and phenotype heterogeneity.
Initial studies performed in the mouse model, identified thymic T cells which had a TCR 
but were negative for CD4 and CDS i.e. double negative (DN). The majority o f these cells 
were found to be CD161 positive and were able to produce large amounts o f IFNy, IL-4 
and TNFa. A population o f CD161/CD4 positive cells with similar abilities to secrete 
these cytokines was also found. The development o f both these subtypes was dependent on 
CD Id. These three populations are present in most o f the tissues and are phenotypic ally 
and functionally distinct.
Biological activity
NKT cells fulfil an important immunoregulatory role in determining subsequent T cell 
responses. Depending upon the ambient cytokine milieau, NKT cells produce substantial 
amounts of IL-4 or IFNy driving Th2 or T hl responses respectively. The dysregulation of 
NKT cell function is thought to play a role in the pathogenesis o f type 1 diabetes in non- 
obese diabetic mice (Sharif, Arreaza et al. 2001), (Hong, Wilson et al. 2001).
IL-12 and co stimulatory pathways play a critical role in modulating the activities o f NKT 
cells (Hayakawa, Takeda et al. 2001).
In humans the DN and CD4+ subsets also exist. Both react with CD Id to produce high 
levels o f IFNy and IL-4 when stimulated.
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The ability o f the TCR of NKT cells to recognise glycolipid in association with CD Id has 
been used in a variety o f experimental models. NKT cells can be rapidly stimulated in the 
murine model using a synthetic glycolipid derived from the marine sponge called alpha- 
galactosyl ceramide (a  gal/cer). Initially the production o f IFNy predominates, however, 
following prolonged stimulation, the profile switches to IL-4 indicating a Tii2 immune 
response.
CD Id  is present on normal kératinocytes. However its expression is up regulated in 
kératinocytes from psoriatic plaques (Bonish, Jullien et al. 2000). Furthermore IFNy is able 
to upregulate the expression of CD Id on human kératinocytes derived from neonatal 
foreskins. The expression o f CD la , CD lb  and C D lc but not CD Id have been described in 
RA synovium (Cauli, Pitzalis et al. 2000).
The ability to induce a psoriatic plaque in ‘norm af skin from a psoriatic patient grafted 
onto the SCID mouse model by injecting the mouse with NKT cells derived from the 
patients’ PB further supports a pathogenic role for these cells in psoriasis (Nickoloff, 
Bonish et al. 2000).
Reduced levels o f NKT cells have been shown in the PB of patients with RA (Yanagihara, 
Shiozawa et al. 1999) and psoriasis (Koreck, Suranyi et al. 2002). The role o f NKT cells in 
PsA has not been studied.
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1.6 Aims of thesis
• To clarify the dominant T cell immune response in PsA
• To identify novel regulatory cytokines in different tissue compartments and assess their 
function in terms o f regulation of Thl responses
• Assess the function o f NKT cells in PsA
• To study the expression o f IL-17 in SM and fluid and its effects on MMP and IL- 6  
production by synovial fibroblasts
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Chapter 2 Material and Methods
2.1 Patients
Glasgow Royal Infirmary Research Ethics Committee granted approval for the project in 
June 2000. Patients with PsA, who were greater than 18 years o f age and capable of 
providing informed consent, were invited to take part in the project. Such patients were 
identified from the PsA Clinic in North Glasgow Trust, Glasgow Royal Infirmary. 
Demographic and disease activity data were collected and stored in a password-protected 
database (SPSS).
PsA was defined if  the following criteria were fulfilled:
(a) Classical psoriatic skin lesion with or without nail involvement.
(b) Peripheral arthiitis alone or in combination with spinal disease.
(c) Negative Rheumatoid Factor (RF) and absence o f subcutaneous nodules.
2.2 Skin biopsy
Elliptical skin biopsy
Patients with active psoriatic plaques were identified. Having identified a suitable plaque 
avoiding the cape area, the skin was cleansed using chlorhexidine gluconate. Thereafter 
1% lignocaine with 1:200000 adrenaline was injected into the subdermis. A 5mm elliptical 
incision was then made using a size 15 surgical scalpel blade. A skin hook and scalpel 
were used to lift the ellipse from the subdermis. The skin was then sutured using 2x 4.0 
Ethilon sutures and a dry Mepore dressing was applied. The incision site was observed for 
30 minutes for bleeding. Patients were informed to attend their practice nurse for suture 
removal at 7-10 days.
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2,3 Synovial biopsy
2.3.1 Blind needle Biopsy
In a subset of patients this procedure was performed rather than arthroscopy due to patient 
preference. The patient was positioned in a semi recumbent position to relax the quadriceps 
group o f muscles. A support was placed behind the knee for comfort. The knee was 
cleansed using alcohol and a drape was placed beneath the knee and over the lower leg. 
5mls o f 1% lignocaine with 1:200000 adrenaline were used to infiltrate the skin as 
previously described. SF was aspirated using a 21G green needle. The knee was then 
infiltrated with 20mls o f 0.5% bupivicaine and rested for 10 minutes. An incision was 
made using a size 15-scalpel blade to the lateral aspect o f the suprapatellar pouch. A 
needle biopsy was used to obtain at least 5 synovial biopsies providing adequate 
representation as per EULAR guidelines.
2.3.2 Needle arthroscopy
Preparation o f  patient and equipment
Patient consent was obtained prior to commencing the procedure and 20mls o f blood were 
obtained for lymphocyte separation, DNA storage and semm. The skin over the lateral 
surface of the knee was shaved and Emla cream was applied to skin portals (supero lateral 
and infero lateral to the patella) 1 hour prior to the procedure.
The patient was positioned as for blind needle biopsy. A sterile paper drape was placed 
under the leg that was cleaned from thigh to ankle with Betadine solution. The leg was
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then placed in a limb bag and a sterile extremity drape placed over the lower limb. A light 
gauze bandage was placed around the ankle.
10"20mls of 1% Lignocaine with 1:200000 adrenaline were used to anaesthetise the portal 
sites and the joint capsule. Using a 20ml syringe and a 21G needle, SF was aspirated from 
the suprapatellar pouch. With the needle left in position, 20mls of Bupivicaine 0.5% 
without adrenaline were injected into the joint cavity. This was allowed to take effect over 
the next 1 0  minutes.
During this time the arthroscopy equipment was prepared. Briefly, a 1 litre bag o f 0.9% 
Sodium Chloride was coimected to an intravenous giving set for joint lavage. The 
arthi’oscope (Karl Stortz) was inserted into a sterile camera sleeve and connected to the 
camera and light source. Prior to arthroscopy, the light source was white balanced.
A longitudinal entry incision was made at the arthroscopy portal sites using a 15-blade 
scalpel. The cannula was inserted using a sharp obturator switching to a blunt obturator 
before advancing into the joint cavity. The blunt obturator was removed and replaced with 
the artlnoscope. A second incision was then made at the biopsy (superior) portal and the 
blunt obturator was used to advance the cannula into the suprapatellar pouch. An irrigation 
line was connected to achieve a constant flow of normal saline through the joint cavity 
allowing clearer visualisation o f anatomy. The joint was carefully inspected for 
macroscopic features of hyperaemia, vascularity, paimus and villous formation (see figure 
2 .1).
Using grasping forceps, synovial biopsies were taken from 6  areas -  lateral, suprapatellar, 
medial, retropatellar, infrapatellar and the cartilage pannus junction (CPJ).
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Biopsies were removed from the forceps using a sterile needle and placed on a gauze swab. 
The samples were then passed to the attending technician for appropriate processing. The 
joint cavity was inspected for any bleeding and irrigated until the saline ran clear. The 
portals were then closed using steri strips and a Mepore bandage. The knee was dressed 
with a pressure bandage and the patient was given advice regarding rest and wound care. In 
addition the patient was given contact numbers in the event o f any problems. The patient 
was reviewed the following week at which time the incision sites were inspected.
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Figure 2.1 PsA SM visualised at arthroscopy.
These appearances are consistent with grade IV synovitis characterised by prominent 
vascularity and villous formation. Note the tortuosity o f blood vessels that distinguish 
these appearances from RA synovitis characterised by straight branching blood vessels.
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2.4.1 Tissue preparation
2.4.1 SM and skin
Tissue sections were prepared and stored for future analysis o f cytokine expression by
immunohistoehemistry and quantitative PCR.
• To obtain frozen sections, SM and skin samples were snap frozen in liquid nitrogen 
after embedding in Cryo-M-Bed embedding compound (Bright Instrument Company, 
Cambridgeshire) on cork discs. 6 pm sections were cut using a cryotome (Bright 
Instruments) at -40°C  and mounted onto silane coated slides. The sections were left at 
room temperature to dry for 1 hour before wrapping in foil and storing at -70°C.
• Paraffin embedded sections were also obtained for future IHC. Tissue was stored in 
formalin and transferred to the pathology department for paraffin embedding and 
subsequent sectioning (David Murray, chief pathology technician). Haematoxylin and 
eosin staining was performed on one o f the serial sections to allow tissue morphology 
to be assessed.
• To facilitate future RNA extraction, tissue sections were homogenised using an electric 
homogeniser (Kinematica, Switzerland) and stored in Trizol reagent (Invitrogen, Life 
Technologies, Scotland) at -70°C prior to processing.
• Finally, explant tissue was transferred to growth medium and cultured at in 
5 %C0 2 /9 5 % O2 to assess tissue production o f cytokine at time intervals. Fibroblasts 
like synoviocytes (FLS) were generated following prolonged incubation and passage of 
cells.
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2.4.2 Cell separation from SF and peripheral blood
Peripheral blood
Wash media was prepared form RPMI containing 2 mM L-glutamine, 100 lU penicillin, 
and 100-pg/ml streptomycin (all obtained from Life Technologies, Paisley, U.K.). Culture 
media were prepared by the addition o f 10% foetal calf serum (PCS) (Sigma) to wash 
medium. 25mis of venesected blood were transferred to 50ml heparinised container and 
diluted with equal volume of RPMI. Blood was carefully layered onto Lymphoprep 
(Nycomed, Oslo, Norway). Samples were centrifuged at 350g for 25 minutes to allow 
separation o f the blood into its component layers. Following centrifugation the interface 
containing PBMCs was carefully removed using a sterile Pasteur pipette and placed in a 
fresh 15ml tube. This PBMC suspension was made up to 14mls with RPMI and 
centrifuged at 350g for 10 minutes to pellet the cells. The supernatant was discarded and 
the pellet resuspended and wash repeated. Cells were finally resuspended in culture media. 
The number of PBMCs was calculated using a haemocytometer (Weber, England). This 
involved making a 1 in 1 0  dilution o f the suspension with cell counting fluid and placing 
lOpl on the haemocytometer under a cover slip. Using a light microscope, the number of 
live cells was counted over 16 squares and averaged over 4 quadrants. This gave a 
calculation o f the number o f cells times 10"^ , This number was then multiplied by the 
dilution factor o f 1 0  and then multiplied by the volume of the suspension to give the total 
number o f cells. The suspension was then adjusted to lOVml
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SF cell isolation
SF obtained at arthroscopy or needle aspiration was transferred to heparinised universal 
containers. Procedure was as for PBMC isolation.
10^ cells were placed in Trizol and stored at -70°C  for future RNA extraction. 
Subsequently, cells were used for co-culture experiments and FACS analysis to deteimine 
spontaneous IFNy expression.
2,5 Identification of Thl cells in PsA SF and PB
2.5.1 Flow Activated Cell Sorting (FACS)
All flow cytometric analysis was conducted using a Becton-Diekinson Fluorescence 
Activated Cell Scanner (FACScan). This flow cytometer measures and analyses the optical 
properties o f single cells passing through a focused argon laser beam. Cell Quest software 
was used to analyse data collected.
2.5.2 Identification of IFNy expressing cells
IFN Y secretion assay
The IFNy secretion assay (Miltenyi, Biotee, Germany) will detect live spontaneous IFNy 
producing leucocytes ex vivo without additional in vitro stimulation, thus cells are 
behaving as they would in vivo (figure 2 .2 )
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Briefly, 10^ cells were re suspended in 300pl RPMI and 50pl removed as negative controls. 
20pi of catch reagent that binds to both CD45 antigen on the surface o f cells and secreted 
IFNy was added to the remainder of the cells and incubated on ice for 15minutes. 10ml of 
warm RPMI/FCS were added to the positive samples and incubated for 45 minutes at 37°C 
with continual rotation. The samples were then topped up to 14mls with cold RPMI and 
washed twice. 20pl o f detection reagent (anti IFNy-PE) were then added to the positive 
samples and 2pi to the negative controls. 8 pi of CD3 FITC Pharmingen (San Diego, 
California) was added to all samples to allow estimation of T cell numbers and incubated 
on ice for lOminutes. Samples were washed with cold RPMI/FCS and resuspended in 
0.5ml o f RPMI for analysis on FACS.
To clarify that this assay was specific for IFNy secreting cells, our laboratory performed 
control experiments. Briefly, T cells separated by a semi permeable membrane were 
stimulated with or without anti CD3 to induce IFNy secretion. Although IFNy passed easily 
through the membrane, no unstimulated T cells stained positive using the double antibody 
assay. This confirmed that the double antibody only detected IFNy released by the CD3 
stimulated T cells. Furthermore, in a second control experiment CD45 positive cells that 
were incapable o f secreting IFNy were mixed with IFNy secreting CD45 positive cells. 
None of the non-secretors identified using a second cell surface marker stained positive 
with the double antibody.
Although not performed in these studies, subsequent purification of IFNy expressing cells 
can be achieved by labelling with magnetic beads coated with anti PE antibody and 
enriched on a column placed within the magnetic field o f a magnetically activated cell 
sorter (MACS, Miltenyi, Biotec, Germany). Thus IFNy expressing magnetically labelled 
cells are retained in the column while the unlabelled cells run through.
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After removal of the o f the column from the magnetic field, the magnetically retained IFNy 
expressing cells can be eluted as positively selected eell fraction and can then be used for 
cell culture and analysis.
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Figure 2.2 Double antibody technique for detecting IFNy expressing cells.
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2.5.3 Identification of Thl markers CCR5 and IL18-R
The identification of stable cell surface markers such as IL-18R and CCR5 in 1998 has 
contributed to the identification o f T hl immune responses in disease states (Xu, Chan et al. 
1998) (Loetscher, Uguccioni et al. 1998). Here we have utilised these markers in PsA PB 
and SF to further determine the predominant immune response.
Matched SF and PBMCs were separated as outlined in section 2.4.2. lO^cells were 
transferred to appropriately labelled FACS tubes. 5pi of CCR5-FITC antibody 
(Pharmingen, San Diego, California) and 8 pi of IL18R-PE (R&D Systems, USA) antibody 
were added together and alone with inelevant PE and FITC controls. Cells were incubated 
on ice for SOminutes then washed with PBS and spun for 6  minutes at 350g. Cells were 
then resuspended in PBS and analysed by FACS.
2.6 Identification of regulatory cytokines by IHC
2.6,1 Frozen sections
Synovium obtained at needle arthroscopy and psoriatic skin tissues were snap frozen in 
liquid nitrogen and 6 pm cryostat sections were cut onto silane coated slides using a 
microtome and stored at -70°C. A range o f antibodies as outlined in Table 2.1 was used to 
label tissue using an indirect immunoperoxidase technique. Briefly, sections were 
rehydrated in PBS then left in methanol/ H2O2 for 30 minutes at room temperature. The 
sections were washed twice in PBS and blocked using 20% serum in PBS o f the species in 
which the secondary antibody was raised. Sections were incubated with previously
80
determined optimal dilutions o f monoclonal antibody overnight at 4 C. The following day 
the sections were washed, incubated with relevant secondary antibody for 30 minutes 
washed twiee with PBS then ineubated with substrate Vector ABC (Vector, Peterborough, 
UK) for 30 minutes. Sections were washed twice in PBS before developing with 0.6mg/ml 
3,3’"diaminobenzidine tetrahydrochloride (Sigma) with 0.01% H2O2 for 5 minutes at RT 
until brown reaction product appeared. Sections were then washed in water and 
counterstained using Harris’s haematoxylin (BDH Ltd. Lutterworth, Leicester, UK). 
Finally sections were dehydrated in ethanol, cleared in xylene then mounted in DPX 
mountant (both from BDH Ltd.).
2.6.2 Paraffin embedded sections
Slides were initially heated to 65°C for 35 minutes. They were then dewaxed in xylene and 
rehydrated through ethanol to PBS. Endogenous peroxidase activity was blocked using 
H2O2 /methanol. To expose the relevant antigen, sections were then microwaved under 
pressure in 1.92g o f anliydrous citric acid (C6H5O7) in 200mls o f distilled water, pH 6 . The 
sections were blocked for 1 hour at RT in 20% serum of the species in which the secondary 
antibody was raised. The relevant primary antibody was applied overnight at 4°C. 
Procedure was then followed as with frozen sections.
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Antibody Manufacturer and clone Source Working Concentration
CD3 Dako mouse monoclonal 5pg/ml
CD6 8 Dako clone PG-M l mouse monoclonal 3.6pg/ml
IL-18 clone E3E1, Andrew Jackson mouse monoclonal 1 pg/ml
IL-17 R&D Goat polyclonal 5pg/ml
IL-12 clone 7.4, Trinchieri mouse monoclonal 12.5pg/ml
Table 2.1 Antibodies for IHC
2.6.3 Quantification of Histology
Quantitative microscopy was performed using an Olympus BX-51 light microscope 
(Olympus Optical Co. Ltd.) with an additional ‘teaching binocular eye piece that allowed 
two observers (Dr J.A. Oracle and the author) to quantify sections simultaneously. 
Synovial tissue was divided into lining layer, sublining layer and lymphoid aggregate if 
present. Dermal tissue was divided into dermis and epidermis. The percentage of positively 
stained nucleated cells were quantified in each area according to the following scoring 
system; 1~ 1-10% o f nueleated cells stained positive, 2=10-25% nucleated cells, 3=25- 
50% and 4=>50% positive.
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2.7 Identification of cytokine mRNA
2.7.1 RNA extraction
RNA designated pipettes and workbench were initially washed with RNAase ZAP (Sigma) 
to avoid contamination of samples with foreign RNA. Samples stored in -70°C  were 
thawed at room temperature (RT). 0.2mls of chloroform (Prolabo, France) were added per 
1ml o f Trizol reagent, shaken vigorously for 15 seconds and left at RT for 3 minutes.
The samples were centrifuged at 12000g at 4°C for 15 minutes. This resulted in the 
formation o f an upper aqueous phase containing RNA, an interface containing proteins and 
a lower organic phase containing DNA. The upper aqueous phase was carefully transferred 
to a clean polypropylene tube and an equal volume o f isopropyl alcohol (BDH Ltd. 
Lutterworth, Leicester, UK) added to precipitate the RNA. A further 10 minute incubation 
at RT was followed by centrifugation at 12000g to pellet the RNA. Following removal of 
the supernatant and washing in 75% ethanol (Hayman, Essex, UK), the pellet was air-dried 
for 5 minutes then resuspended in 22pl o f sterile water and incubated at 55°C for 10 
minutes.
RNA concentration was calculated by measuring the optical density (O.D) reading of a 50- 
fold RNA dilution at a wavelength of 260mn and 280nm using a Bio quest (Cecil 
Instruments, Cambridge England) spectrophotometer. This process assumes that an OD of 
1 is equivalent to 40pg/ml of RNA. The purity o f the sample was assessed from the ratio of 
the OD at 260mn to the OD at 280mn.
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2.7.2 DNAse treatment of RNA
All PCR work was carried out at designated PCR bench in the laboratory using PCR 
designated pipettes. In certain TaqMan PCR reactions such as IL-18, genomic DNA is 
amplified as primers may span introns. In this case the RNA was required to be DNAse 
treated prior to RT PCR. This was achieved by pre incubation with RNAse free DNAse 
(Ambion Inc, RNA Diagnostics, Huntingdon, Cambridgeshire) for 15minutes at 37°C, 
65°C for 10 minutes to inactivate the enzyme, before commencing the RT PCR reaction as 
above.
p  Ac tin PCR
24pi of mastermix was made containing 2.5pl o f 2mM dNTPs (Life Technologies), 2.5pl 
of lOxPCR reaction buffer, 1.5 pi of magnesium chloride (AB Gene), 0.125 pi o f Taq 
polymerase (AB Gene), Ip l each of 5 primer and 3 primer for (3 actin and 15.375pl of 
sterile water. Ip l o f cDNA was added to 24pi of mastermix. The PCR reaction was 
performed on a Genius PCR maehine (Techne).
2.7.3 Reverse transcription of RNA
5pg of the total RNA obtained from PBMCs and SFCs was reverse transcribed to its 
corresponding cDNA. Initially each sample was made up to 11 pi using sterile water. 1 pi of 
random primer (Life Teehnologies, Invitrogen, Paisley) was added to each sample and 
incubated at 70°C for 10 minutes. 7pl of reaction mix containing 2 pi of PCR reaction 
buffer, 2 pi magnesium chloride (AB Gene House, Suney, UK) and 2pl of O.IM DTT
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(Gibco BRL) and Ip l of lOmM dNTPs (Life Technologies) were added to eaeh sample 
giving a total volume o f 19pls. The samples were transferred to the Genius PCR machine 
(Techne Ltd.) and incubated for 5 minutes at 25°C. During a pause in the programme, Ip l 
o f superscript (Life Technologies, Invitrogen, Paisley) was added and the programme 
recommenced as follows: 10 minutes at 25°C, 50 minutes at 42°C and 10 minutes at 70'"C. 
On completion the cDNA was stored overnight at 4°C. PCR for p-actin was performed to 
establish successful RT PCR.
2,7.4 Agarose gel electrophoresis
A 2% agarose gel (Bioline Ltd., London) containing 0.001% ethidium bromide (Sigma) 
was set in a casting tray containing a 20-toothed comb. The gel once set was placed into a 
gel tank (Life Technologies, UK) and overlaid with IxTBE buffer. A IkB DNA ladder 
(Advanced Biotechnologies, Surrey, UK) was also loaded onto the gel to allow sizing and 
appropriate quantification o f the products within the sample. lOpl of sample with 5pi of 
orange G solution containing 50% glycerol and 10% TBE were added to individual wells. 
The samples were then electrophoresed at 100 volts for 60 minutes to allow migration of 
the cDNA within the gel from cathode to anode. The gel block was then removed and 
visualised using camera and UVI-photo software programme.
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2.7.5 TaqMan PCR
TaqMan (Applied Biosystems, California, USA) is used as a research tool for real time in 
vitro relative quantitative evaluation o f gene expression. It has the advantage over standard 
PCR in that it identifies gene expression in small tissue samples.
Ip l of cDNA was added in triplicate to Universal PCR reaction mix (AmpliTaq Gold DNA 
Polymerase, AmpErase UNG, dNTPs with dUTP, passive reference and optimised buffer 
eomponents) in microcentrifuge wells in a 96-well plate. The primers and probe o f the 
gene of interest were than added to the samples. To quantify the relative expression of the 
gene o f interest, a housekeeping gene HPRT was analysed in each sample triplicate.
The following human IL-18 primers were used: forward primer
CGCCTCTATTTGAAGATATGACTGATT, probe TGACTGTAGAGATAATGC 
ACCCCGGACC and reverse primer CCTCTAGGCTGGCTATCCTTTATACA TACT. 
The PCR amplification reaction was performed (45 cycles) by ABI Prism 7700 Sequence 
Detection System. Products were expressed as a percentage o f HPRT.
IFNy TaqMan primers (Applied Biosystems) were provided in combination with the IFNy 
probe as a pre-developed primer and probe reagent.
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2.8 Analysis of cytokine expression in SF and serum
2.8.1 IL-18 ELISA
IL-18 levels were measured in SF supernatants and serum using a commercially available 
solid phase sandwich ELISA (Diaclone, France). Briefly, 100pi of sample were loaded into 
wells precoated with polyclonal specific 11-18 antibody. Following the addition of 
biotinylated anti IL-18 antibody, samples were incubated at RT for 3 hours. The plates 
were then washed thrice and lOOpl of streptavidin HRP (working dilution 1:2500) were 
added to each well. The plates were then incubated at RT for a further 45 minutes. 
Following a further wash step, lOOpl of tertramethyl benzidine (TMB) solution were added 
to each well until the reaction developed. The reaction was halted using 50pl of 
O.2 MH2SO4 , A MRX II microplate reader (Dynex) was used to determine absorbency at 
450mn, A standard curve ranging from 62.5-2000pg/ml was constructed and the IL-18 
content o f the samples calculated. The minimum detectable dose o f IL-18 by this assay is 
<45pg/ml.
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2.8.2 IL-17 ELISA
IL-17 levels were measured in serum and SF using anti IL-17 monoclonal antibody 
(MAB317, R&D) as a capture antibody and biotinylated IL-17 polyclonal antibody as a 
detection antibody on a sandwich ELISA (BAF 317, R&D). A standard curve was 
constructed ranging from 31.25 to 2000pg/ml. Subsequent procedure was followed as for 
IL-18 ELISA.
2.8.3 IL-12p40 and IL-12p70 ELISA
IL-12p40 levels were measured in serum and SF using a eommercially available ELISA 
(Biosource). The procedure was the same as described for TN Fa ELISA (section 2.9.4).
2.9 Analysis of cytokine function
2.9.1 SFC and PBMC isolation and stimulation
SF and 3Omis of matched PB were obtained at either needle arthroscopy or needle 
aspiration from patients with active PsA defined as the presence o f detectable synovitis of 
the knee. SF cells (SFC) and PBMCs (PBMC) were isolated as outlined in section 2.4.2. 
Cell numbers and viability were determined with trypan blue exclusion. Cell numbers were 
adjusted to 10  ^ viable cells/ml and lOOpls added to each well o f a 96 round bottom well 
plate (Cellstar). Cells were cultured in RPMI/FCS. Recombinant cytokines IL-12 (liig/ml), 
IL-18 (lOOng/ml), IL-15 (Ing/ml) were added singly or in combination to wells in 
triplicate to a final volume o f 200pl/well. The working cytokine concentrations have been 
demonstrated to be the optimal concentration for cell stimulation in studies by this 
laboratory. Supernatants were harvested after 24 hours incubation at 37°C with 
5 %C0 2 /9 5 % 0 2  and assayed for TN Fa and IFNy content using specific IFNy and TN Fa 
ELISA (BioSource International, Hertfordshire, UK).
2.9.2 Co-culture with CD3 and CD28
The T cell reeeptor is expressed on T cells in association with a group of 5 invariant chains 
termed CD3. It is essential for TCR stabilisation and signal transduetion. In cytokine co­
culture experiments therefore, 96 well fiat-bottomed plates were coated with anti CD3 
antibody (200ng/ml) (Skybio, clone UCHT-1, UK) in PBS pH 9.6 for 24 hours at 4°C.
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Wells were then washed twice with RPMI. SFC and PBMCs were adjusted to 10^/ml in 
RPMI/FCS and cultured at 10^ cells per anti CD3 immobilised wells with recombinant 
cytokines.
CD28, the principal receptor for B7.1 and B7.2 co stimulatory molecules expressed on 
APC, was added to provide additional T cell activation. Cells were cultured for 24 hours at 
37°C in 5 %C0 2  after which supernatants were removed and stored at -20°C for future 
TN Fa and IFNy expression by ELISA.
2.9.3 Proliferation after culture with recombinant cytokines
Following removal o f 200pl supernatant for ELISA, 200pis of RPMI/FCS were added to 
the remaining cells. To assess proliferation response to recombinant cytokines, cells were 
pulsed with 0.5pCu ^H-Thymidine (Amersham International Pic.) and ineubated at 37°C in 
5 %C0 2 / 0 2  for 8 houi's. Cells were then harvested onto glass fibre filter paper (Packard 
Instruments, Netherlands) using a cell haiwester (Packard Instruments, Netherlands). ^H- 
Thymidine uptake was determined by counting samples on a MatrixTM 96 Direct Beta 
counter (Packard Instruments, Netherlands).
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2.9.4 Assessment of IFNy and TNFa in culture supernatants.
T N F a  ELISA
TN Fa levels in culture supernatant were assessed using a commercially available solid 
phase human TN Fa ELISA (Biosource). Briefly, the ELISA plate was eoated overnight at 
4°C with lOOpl of anti TN Fa (5pg/ml) in O.IM NaHCOa pH7.4.
The following day, the plates were blocked with 2% milk in PBS for 1 hour at RT, Plates 
were washed tluice using PBS/0.1% Tween and standard curve for TN Fa ranging 
2000pg/ml to 31.5pg/ml were added to the first two eolumns. lOOpl of sample and 50pl of 
biotinylated anti TN Fa antibody (0.4pg/ml) were added in triplicate and incubated at room 
temperature for a further 2 hours. Procedure thereafter was as for IL-18 ELISA.
IFNyELISA
The IFNy content o f the culture supernatant was assessed using a commercially available 
solid phase human IFNy ELISA (Biosource) with sensitivity o f <4pg/ml. Range o f 
detection from 15.6-lOOOpg/ml. Coating antibody was used at 2pg/ml. Blocking was 
achieved using 0.5% BSA for 2 hours at room temperature. Biotinylated secondary 
antibody was used at 0.4pg/ml.
Results from all ELISA experiments were transposed into graphic format using Microsoft 
Excel© software.
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2.10 Effect of IL-17 on synovial derived fibroblasts
The ability o f fibroblasts to respond to IL-17 in culture was investigated based on the 
obseiwation that this Thl derived cytokine plays an integral part in inducing MMP 
expression in RA (Chabaud, Garnero et al. 2000). The ability o f PsA synovial derived 
fibroblasts to express MMP-3 and IL - 6  was investigated.
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2.10.1 Establishing fibroblast population
SM and SF were obtained as previously described (section 2.3). Dissected membrane and 
fluid were added to RPMI/FCS and incubated at 37°C in 5 %C0 2 /0 2 . After 24 hours, 
supernatants were removed and stored for future cytokine expression by ELISA. The 
medium was replaced and cells cultured with regular medium changes until fibroblasts 
became confluent. They were washed with PBS once to remove any residual RPMI, 
Adherent fibroblasts were lifted into solution by adding Ix trypsin EDTA (Sigma) for 15 
minutes at 3 7 °C. The fibroblasts were then washed in RPMI by centrifugation at 350g for 
5 minutes. The fibroblast pellet was resuspended in RPMI/FCS and incubated at 37°C in 
5 %C0 2 /0 2 . Once fibroblasts had become confluent, this process of trypsinisation was 
repeated until at least passage 3 at which point fibroblasts were used for co-culture 
experiments with recombinant cytokines.
2.10.2 Cytokine stimulation of fibroblasts
Fibroblasts at passage 3- 4 were trypsinised and washed with RPMI. Equal numbers of 
eells (at least 10"^ ) were added to 96 well flat-bottomed culture plates in triplicate. 
Fibroblasts were incubated at 37°C in SVaCO^Oj for 5 days for cells to come to 
confluenee. Recombinant IL-17 (5ng/ml) and IL-22 (300ng/ml) were then added alone or 
in combination to determine whether they had any anti or pro-inflammatory effects on 
synovial derived fibroblasts. Following 24 eulture at 37“C in 5 %C0 2 /0 2 , supernatants were 
removed and stored at -20°C  until measurement o f MMP-3 and IL- 6  by ELISA.
93
2.10.3 IL-6 and MMP expression by synovial fibroblasts
IN 6  ELISA
A commercially available IL - 6  ELISA was used (Biosource). Protocol was identical to that 
o f T N Fa substituting for anti-IL- 6  specific antibodies. Sensitivity for this assay is 2pg/ml 
with a range from 15-1500pg/ml.
MMP-3 ELISA
MMP-3 content of fibroblast supernatant was assessed using a commercially available 
ELISA kit (Amersham Pharmacia Biotec, UK), which provided plates, precoated with 
human anti MMP-3 antibody. Standards and samples were added to the plate and incubated 
for 1 hour at 4°C. After washing thrice with wash buffer provided, lOOpl of peroxidase 
conjugate and anti MMP3 antibody were added for 2 hours at room temperature. M MP3 
content of samples was determined using TMB substrate and halted using 50pl of 
O.2 MFI2SO4 . A microplate reader (Dynex Technologies MRXII) was used to determine 
absorbency at 450mn. A standard cui"ve was constructed starting at 120ng/ml and 
thereafter content of the samples calculated. The range for this assay was 3.75-120pg/ml.
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2.11 IL-18 processing
2.11.1 MAP kinase inhibition
Triplicate wells of matched PBMC / SFMC (10^ eells / well) in 10%FCS / RPMI were 
incubated with recombinant IL-12 (1 ng / ml) ± IL-18 (100 ng / ml) in the presence or absence 
o f the p38 MAPK inhibitor SB203580 from Alexis (Nottingham, U.K.) or DMSO earner 
control for 24 hours at 37°C. Supernatants removed after 24 hours were examined for IFN- 
y and TN F-a production by ELISA. Subsequent proliferation o f PBMC / SFMC was 
assessed at 72 hours by ^H-thymidine uptake during the final 8 hours o f culture.
2.11.2 ATP dependant release of IL-18 and IL-lp by SFCs
SFMC were obtained by Ficoll hypaque (Sigma) separation as previously described and 
suspended in RPMI/FCS. Viable cells were added to 48 well culture plate at 2x 10  ^
cells/well and stimulated with LPS (Sigma) at lOng/ml and lOOng/ml concentrations. After 
1 or 2 hours incubation at 37°C in 5 %C0 2 /9 5 % 0 2  supernatants were removed and replaced 
with fresh medium containing 50mM Benzyl ATP (Sigma) to induce cytokine release. 
Following a further 20 minutes incubation, supernatants were removed and stored at -20°C 
for subsequent measurement o f IL -ip  using a commercially available ELISA (Biosource). 
Procedure was the same as for TN Fa ELISA substituting anti TN Fa antibodies with anti 
IL -ip  antibodies. Standards were constructed ranging from 2000-37,25pg/ml with 
sensitivity o f <10pg/ml. IL-18 levels were similarly measured in supernatants as previously 
described.
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Chapter 3 Characterisation of PsA cohort
Although there has been considerable progress in the investigation of genetic and 
immunological factors in the pathogenesis o f PsA, there remain major difficulties in the 
development o f diagnostic and classification criteria. This problem has led to an 
international project aiming to derive definitive diagnostic criteria, that will in turn 
represent a major advance in future research into this complex disease. For purposes o f this 
thesis, PsA was diagnosed in patients with an inflammatory arthritis in the presence of 
psoriasis. Patients with seronegative disease and definite first-degree family history of 
psoriasis were also included. Patients were defined as having RA with psoriasis if  nodules 
and/or rheumatoid factor were detected.
Previous studies have indicated that community and hospital PsA cohorts differ in teims of 
mortality and disease severity (Wong, Gladman et al. 1997). To determine whether the 
hospital based PsA cohort studied in this thesis was representative o f similar hospital based 
cohorts, demographic and disease activity data were collected from patients attending a 
dedicated weekly PsA clinic at Glasgow Royal Infirmary established in summer 2000. 
Patients attending this clinic are referred from the community by their general practitioner 
with a probable diagnosis o f PsA or from rheumatology or dermatology hospital clinies 
where other consultant physicians suggested the diagnosis o f PsA. Data regarding age, sex, 
duration of arthi’opathy and psoriasis, family history and smoking status were collected. 
DMARD use and pattern o f disease was recorded. Acute phase parameters (ESR and CRP) 
were measured. Clinieal measures o f disease activity (swollen and tender joint counts) 
were collected over a 4-week period in January 2002. A subset o f patients, prior to clinic 
attendance, completed a health assessment questionnaire (HAQ) (see Appendix B) to
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assess disability. Originally designed for use in RA and OA, the HAQ takes approximately 
5 minutes to complete and provides a score from 0 (no disability) to 3.0 (complete 
dependence on others). Data were stored and analysed using a password-protected database 
with statistical package (SPSS).
3.1 Demographic characteristics of PsA cohort
Data were collected from 180 patients over a 2-year period from August 2000 to July 2002. 
Approximately 25 patients were seen per week during this period by the author and 
Professor I.B.McInnes at Glasgow Royal Infirmary. 48% o f this cohort was male and 52% 
female. The mean age was 44 years with a range from 17 to 75 years. Mean disease 
duration of PsA and psoriasis was 10 and 19 years respectively. There was a positive first- 
degree family history o f PsA or psoriasis in 56% of cases. 70% were non-smokers, 13% 
ex-smokers and 17% current smokers.
ESR, CRP, swollen and tender joint counts were used to estimate disease aetivity. The 
mean ESR was 20mm/hr (range l-74mm/hr) and the mean CRP was 17mg/l (range 6 - 
89mg/l). 50% of patients did not exhibit an elevated acute phase response at any stage.
A cross-sectional subset of 34 patients was examined for the presence o f tender and 
swollen joint counts over a 4-week period. The mean number o f swollen joints was 6  
(range 0 - 4 1 ;  SD 8 .6 ). Mean tender joint counts were 15 (range 0-64; SD 19.6). 30 
patients completed a HAQ questionnaire to assess functional impact of disease. The mean 
for this group was 1.3 (range 0-3; SD 1.12).
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Mean Range
Age (years) 44 17-75
PsA disease duration (years) 1 0 1-35
Psoriasis disease duration (years) 19 1-71
ESR (mm/hr) 2 0 1-74
CRP (mg/1) 17 6-89
Table 3.1 Demographics of PsA cohort.
The demographies o f 180 PsA patients are shown. Mean values are shown with range of 
values. ESR <15mm/minute normal reference; CRP <10mg/ml normal reference.
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3.2 DMARD therapy in PsA cohort
DMARD use has been characterised in other PsA cohorts and thus it was important to 
document DMARD use in the present study. Moreover, since these agents are themselves 
potentially immune modulatory and since the subject matter o f the project concerned 
immune function it was important to establish at the outset typical DMARD use. DMARD 
use was captured at entry to the cohort, reflecting therefore general prescribing activities 
prior to the establishment of the cohort.
80% of patients attending the PsA clinic were receiving DMARD therapy. The most 
commonly prescribed DMARD was methotrexate (35%) followed by sulphasalazine 
(29%). The remainder of DMARD therapies employed were: sulphasalazine and 
methotrexate (2%), injectable gold (4%), hydroxychloroquine (2%). The remaining 8 % 
were prescribed a variety of less commonly prescribed DMARDs in PsA such as 
penicillamine, azathioprine and cyclosporin.
3.3 Disease patterns
In the absence of validated diagnostic criteria for PsA, the concept of disease subgroups is 
problematic. In this study, patients were classified on the basis of peripheral joint disease 
alone, axial disease alone, or a combination o f axial and peripheral disease. Other 
subgroups such as those with DIP involvement, enthesitis alone and arthritis mutilans 
were also recorded. The majority o f patients attended with peripheral artliritis alone (52%) 
or in combination with axial disease (29%). The remainder of patients attended with 
enthesitis alone (2%), DIP involvement alone (1.3%), and arthritis mutilans (2.5%). 4 
patients were diagnosed with seropositive RA and psoriasis rather than PsA. Subgroup
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analysis o f sex incidence in axial and peripheral disease was performed. In those with axial 
disease alone there was equal sex incidence. In those with a combination o f peripheral and 
axial disease, there was a slight male predominance o f 1.4:1 whereas in those with 
peripheral disease alone there was a female predominance o f 1.3:1.
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Figure 3.1 DMARD use in PsA cohort
DMARD history was obtained from 180 patients attending the PsA clinic. Methotrexate, 
(MTX), Sulphasalazine (SASP), Hydroxychloroquine (HCQ), gold sodium thiomalate 
(GST). Other therapy included penicillamine, cyclosporin or azathioprine.
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Figure 3.2 Histogram of disease patterns
Pattern o f disease expression was categorised using criteria based on Helliwell. Patients 
were examined for evidence o f axial disease, peripheral joint involvement or a 
combination o f both. Patient with a positive rheumatoid factor were categorised as having 
psoriasis and rheumatoid arthritis. Arthritis mutilans, distal interphalangeal involvement 
(DIP) and enthesitis alone were categorised separately.
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Male Female
Spondyloarthropathy (11) 6 5
Peripheral arthritis (63) 27 36
Combination (36) 2 1 15
Table 3.2 Sex incidence in disease subsets
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3.4 Discussion
PsA is a heterogeneous disease characterised by joint and skin inflammation o f varying 
severity. The heterogeneity o f disease expression changes over time making this a 
particularly complex disease to characterise. As such, there are only two large hospital 
based PsA cohorts in which the clinical spectrum of disease patterns has been described.
Clinical, radiological and biochemical data from a Canadian cohort o f 220 patients were 
studied to determine the prevalence o f clinical subsets within PsA. Their results confirmed 
a spectrum of disease pattern and severity; polyarthritis was the most common joint pattern 
affecting 61% o f the cohort (Gladman, Shuckett et al. 1987): 40% had a deforming, erosive 
arthropathy of whom 17% had five or more deformed joints; 28% exhibited an asymmetric 
oligoarthritis.
In a second cohort, clinical and radiological features o f 100 patients with PsA were 
examined to determine features that may be associated with functional disability. 
Asymmetric oligoarthritis was the commonest presentation occurring in 43%. Symmetrical 
polyarthritis was documented in 33%. This latter subgroup had the highest number of 
erosions and deformities. Sacroiliitis was a feature in 14% with predominant spondylitis in 
4%. Arthritis mutilans was rare occurring in only 2% of this population (Veale, Rogers et 
al. 1994).
Our data indicate that peripheral artliritis with or without axial disease accounts for the 
majority o f cases. These findings are consistent with other hospital-based cohorts as 
previously described and as such are representative o f the spectrum of disease patterns
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seen in hospital based PsA cohorts. Our data may not be representative o f PsA as a whole 
as hospital based cohorts are likely to over represent the severity o f either psoriasis, 
arthritis or both. M ost patients with mild disease are often managed in the community. 
Patients with both psoriasis and arthritis are more likely to be referred to a secondary or 
tertiary centre than those with either condition alone resulting in an overestimate of the 
occurrence o f psoriasis and arthritis. Thus extrapolation o f hospital-acquired data to the 
general population may not be valid. In community-based cohorts, DMARD use is 
estimated to be approximately 1%. This is in contrast with our cohort where the DMARD 
use is 80% reflecting more severe disease. The spectrum o f disease subtypes also differs 
between the hospital and community based PsA cohorts. Community studies indicate a 
predominance o f oligoarthritis affecting 91% of patients (Shbeeb, Uramoto et al. 2000) in 
contrast to hospital-based cohorts where the commonest presentation is polyarthritis alone 
or in combination with axial disease.
Finally, increased mortality is described in hospital-based cohorts reflecting increased 
disease severity (Wong, Gladman et al. 1997) whereas no such increase is found in 
community based PsA cohorts.
The overall male to female ratio in this cohort was approximately 1:1 consistent with 
previous reports (Gladman 1998). The findings o f a slight male predominance in the axial 
disease group and female predominance in the peripheral artlnitis group are consistent with 
previous studies.
In conclusion, it would appear that our cohort is representative o f other hospital based PsA 
cohorts and therefore is representative of the more severe end o f the disease spectrum. The 
following studies performed on this group of patients and the conclusions drawn camiot 
however be extrapolated to PsA population as a whole.
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Chapter 4 Characterisation of T cell immune response in PsA
There is strong evidence that T cell effector function is implicated in psoriasis and PsA. 
In psoriasis T cell activation, T cell receptor repertoire skewing and the beneficial clinical 
effects o f T cell depleting therapies such as cyclosporin and PU VA (psoralen + ultraviolet 
A) indicate that T cells, driven by local antigen recognition, play an important role in 
pathogenesis (Ortonne 1996). The role of T cells in PsA is less well defined than in 
cutaneous disease. T cells of various phenotypic subsets are prominent in inflamed SM 
(Braathen, Fyrand et al. 1979) and o f activated phenotype. Oligoclonality of synovial T 
cells further suggests that they are recognising local antigen, and that similar recognition 
may occur in skin and synovial compartments (Tassiulas, Duncan et al. 1999) (Borgato, 
Puccetti et al. 2002). Moreover, T cells detected in SF demonstrate a predominance o f 
CD 8 ^ lymphocytes with restricted T cell V(3 gene expansion (Costello, Winchester et al. 
2001). The clinical benefit o f alefacept, a T cell specific agent, suggests that such T cells 
have a pathogenic role in PsA (Kraan, van Kuijk et al. 2002).
The effector function o f T cells in psoriasis is considered to be o f Thl phenotype (Schlaak, 
Buslau et al. 1994). The beneficial effects o f fumarates that down regulate IFNy expression 
supports this hypothesis (Litjens, Nibbering et al. 2003) (Ockenfels, Schulte wo Iter et al. 
1998). I first sought to evaluate whether the same was true o f the synovial T cell response 
in PsA.
106
4.1 T cell expression in PsA SM and skin
I first characterised the presence and phenotype o f T cells in the SM and involved skin of 
patients with PsA. Parallel 6 pM cryostat sections o f matched, involved skin and SM 
obtained by skin biopsy and needle arthroscopy respectively were stained using anti-CD3 
antibodies. Tonsil was used as positive control. Irrelevant primary and secondary 
antibodies were used to clarify specificity o f staining. CD3^ rich infiltrates were observed 
in all PsA SM (figure 4.1 A) and involved skin samples examined (n=8 ) (Figure 4 .IB). In 
skin, T cell expression was detected in the dermis and epidermis. In SM, there was staining 
detected in the sub-lining layer and in lymphocytic aggregates suggesting lymphocytic 
distribution in both diffuse and organising secondary lymphoid structures. No staining was 
detected in the SM lining layer. Positive perivascular and endothelial staining was detected 
likely representing lymphocytes captured during diapedesis. These data clearly 
demonstrate the presence of T cells within PsA SM and psoriatic skin in patterns 
reminiscent o f those described previously, confirming the relevance o f this tissue cohort 
for further characterisation.
4.2 Phenotype of T cell Response in PsA
I next sought to determine the functional phenotype of this T cell infiltrate. Functional 
heterogeneity in Th cells has been clearly established in rodents and human tissues 
(Mosmami, Cherwinski et al. 1986). Thl cells produce IFNy and IL-17, and are marked by 
selective expression o f several membrane markers including CCR5, IL-12Rp and IL-18Ra 
(Loetscher, Uguccioni et al. 1998; Xu, Chan et al. 1998). Th2 cells in contrast secrete IL-4, 
IL-5 and IL-13 and express CXCR3 and ST2 (Xu, Chan et al. 1998). Differential
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transcription factor expression further delineates the functional subsets, such that Thl cells 
express t-bet and Th2 cells GATA-3 (Rengarajan, Szabo et ah 2000)). The balance 
between these subsets determines disease phenotype and progression in many experimental 
models and potentially in clinical disease states, although definitive identification o f in 
vivo activated human T hl cells is relatively lacking in the literature, primarily due to 
teclmical constraints on analysis o f human tissue derived T cell subsets. Thus elucidation 
o f predominant Th responses and factors regulating their maturation and effector function 
clearly carries important implications for understanding autoimmune disease pathogenesis.
4.2.1 Expression of IFNy mRNA in PsA SM, SF and psoriatic skin
I initially sought expression o f IFNy by SF MCs, involved skin and SM at the mRNA 
level. Quantitative PCR was employed (TaqMan) on cDNA derived from involved skin 
and SM and fluid obtained at needle arthroscopy on tissues that were immediately snap 
frozen. Successful reverse transcription to cDNA derived from tissue and SF cells was 
confirmed by RT-PCR to demonstrate the presence of p-Actin. IFNy mRNA expression 
was detected in involved skin, SF MCs and SM in every sample that was examined, 
indicating that IFNy expression is ubiquitous in disease derived tissues. mRNA levels of 
IFNy normalised to HPRT in psoriatic skin were greatly increased compared with SM and 
fluid MCs (Figure 4.2).
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4.2.2 Detection of IFNy in PsA SF
IFNy expression was next measured at the protein level in PsA SFs. In previous studies this 
has been used as an indicator o f Thl responses in vivo. Consistent detection of such protein 
expression has however proven elusive reflecting perhaps in part inadequate available 
technology. ELISA was used to detect IFNy expression in SFs from 12 patients with 
active PsA undergoing needle arthroscopy or joint aspiration as clinically indicated. By 
this method, detectable levels o f IFNy were present above the lower limit o f sensitivity 
(18pg/ml) in only 2 o f 12 samples supernatants examined (Figure 4.3).
4.2.3 IFNy expression in RA and PsA SF cells
Thus, although IFNy mRNA is readily detectable, consistent protein expression has proven 
difficult to demonstrate. It was therefore important to identify whether IFNy releasing cell 
populations were detectable in the synovial compartment. Detection of intra-cellular 
cytokine expression in mitogen stimulated T cells ex vivo in the presence o f brefeldin has 
been widely employed. This assay however measures the mitogen responsive population 
rather than truly reflecting cell subsets expressing IFNy in response to native in vivo 
stimulus. 1 therefore employed a novel cytokine estimation technique utilising bivalent 
antibody specificity / FACS analysis to identify spontaneous IFNy producing cells ex vivo. 
The identification o f such cells, should provide definitive evidence that Thl responses 
predominate in PsA.
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SF and PBMCs from patients with active RA and PsA were labelled with a double 
antibody recognising CD45 antigen and IFNy as demonstrated in Figure 2.1. The mean 
percentage o f CD3+ T cells spontaneously expressing IFNy in PsA was 12.56% compared 
with 2.5% in RA SF (p<0.001) (Figme 4.4). In a subset of patients CD3 negative cells, 
most likely NK cells, were also shown to contribute significantly to IFNy secretion (Table 
4.1). These data clarify for the first time the magnitude of the Thl response in PsA. 
Importantly and unexpectedly, they clearly distinguish RA from PsA SF T cell subsets.
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Figure 4.1 T cell infiltration in PsA SM and lesional skin
Immunohistochemical analysis o f psoriatic SM (A) and involved skin (B). Cryostat 
sections (6pM) were acetone fixed and stained with anti-CD3 monoclonal antibody. 
Primary antibody was detected with biotinylated anti mouse IgG antibody and developed 
using the avidin/biotin complex immunoperoxidase method and diaminobenzidine for 
colour development (brown).
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Figure 4.2 IFNy mRNA expression in PsA and psoriasis
Real Time quantitative PCR was performed to detect human IFNy expression in PsA SM
(n=8), skin (n=4) and SF MC lysates (n=8). Expression o f IFNy mRNA was expressed as a
percentage o f HPRT. Data shown are mean ± s.e.m o f triplicate assay.
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Figure 4.3 IFNy protein levels in PsA SF
SF from PsA (n=12, patients A-M) patients were obtained at needle arthroscopy or joint 
aspiration. Fluids were analysed for the presence of IFNy by ELISA. In most cases there 
was little or undetectable levels o f IFNy found in the SF supernatants. Data are mean ± 
s.e.m o f triplicate assay.
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Figure 4.4 Spontaneous IFNy expression by SF and PBMC in RA and PsA
Double antibody FACS analysis was performed on SF cells derived from patients with 
active PsA and RA. Lymphocyte population was gated initially on forward and side 
scatter. IFNy expression was increased in the PsA cells compared with RA cells. Data are 
representative o f 11 experiments in the PsA group and 7 in the RA group. Data represent 
the percentage o f gated cells with upper right being % IFNy positive cells.
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Percentage IF Sy secretion
CD3^population CD3'population
P sA l
PBMC 7 21
SFC 8 30
PsA 2
PBMC 2.7 1.3
SFC 5.6 1.3
PsA 3
PBMC 8.5 14.5
SFC 19 1.5
PsA 4
PBMC NA NA
SFC 39 2.2
Table 4.1 Matched PB and SFMC in CD3 and CD3 populations seerete IFNy.
Matched SF and PBMCs were labelled with FITC conjugated anti CD3 antibody and PE 
conjugated anti IFNy detection antibodies following incubation with IFNy capture 
antibody. The percentage o f CD3^ and CD3" cells that spontaneously secrete IFNy is 
shown.
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4.3 CCR5/IL18-R expression in PsA
IL-18Ra and CCR5 expression by PsA SF and matched PBMCs was determined to further 
clarify T hl responses in PsA.
IL-18Ra is selectively and persistently expressed on Thl cells (Xu, Chan et al. 1998) 
making it a useful marker for distinguishing Thl from Th2 responses in fluid and tissue 
compartments in disease states. CCR5 has been detected at high levels in Thl cells with 
virtual absence from Th2 cells. Immunohistochemistry demonstrates intense CCR5 
expression in RA synovium T cell aggregates with relative paucity o f the surface 
membrane Th2 marker CCR3 (Loetscher, Uguccioni et al. 1998).
SF and matched PB were obtained from patients with active PsA. MCs were obtained by 
density gradient centrifugation and immediately incubated with anti CCR5 and anti-IL-18R 
antibodies conjugated with FITC and PE respectively. Negative controls were included to 
allow accurate gating of positively stained cells by FACS analysis (Figure 4.5). 
Percentage o f cells positive for CCR5 and IL-18R in PB compared with SF is 
demonstrated figure 4.6.
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Figure 4.5 CCR5 and IL-18R expression by PsA SF MCs
FACS analysis was performed on SF cells from patients with active PsA. Data 
representative o f 5 experiments (presented in figure 4.6). 25% o f gated cells stained with 
both CCR5 and IL18-R antibodies (bottom panel).
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Figure 4.6 CCR5 and IL-18R expression by SF and PBMCs.
Percentage of SF and PB MCs expressing IL18R and CCR5 was calculated using PE 
labelled anti IL-18R and FITC labelled anti CCR5 antibodies and FACS analysis.
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4.4 TNFa expression in PsA
I next sought to determine the functional significance o f IFNy expression in PsA. There are 
several mechanisms whereby IFNy may induce inflammation in PsA.
• IFNy is the prototype macrophage activator o f TN Fa and as such may exert its pro 
inflammatory effects in PsA skin and joints via induction of TNFa. The beneficial 
effects o f TN Fa blocking therapies indicate that elevated levels o f TN Fa in PsA 
are of functional significance (Mease, Goffe et al. 2000).
• Secondly IFNy may itself be pathogenic in psoriasis and PsA. IFNy used in clinical 
trials as a treatment for psoriasis resulted in the development of inflammatoiy 
arthi'itis that resolved with cessation o f treatment. Réintroduction of IFNy led to a 
relapse of symptoms (Fierlbeck and Rassner 1990). Furthermore, local psoriatic 
lesions occun'ed at the injection sites in a subset o f cases (Fierlbeck, Rassner et al. 
1990).
To explore whether IFNy may induce TN Fa expression in our cohort, it was important to 
determine whether TN Fa expression was expressed in tissue and fluid compartments.
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4.4.1 TNFa mRNA expression by PsA SFCs
I initially sought expression o f T N Fa at the message level in SF MCs. RNA was extracted 
from isolated SF MCs using TRIzol reagent. RT-PCR was performed to obtain cDNA. 
Successful RT PCR was confirmed by demonstrating the presence o f P actin using 
standard PCR and gel electrophoresis. Samples were then assessed for the expression of 
TN Fa mRNA.
TN Fa mRNA was detected in all samples studied (Figure 4.7)
4.4.2 Spontaneous TNFa expression by PsA SFC and PBMCs
I next sought to determine spontaneous TN Fa expression by PsA SF and PBMCs 
compared witb normal PBMCs. Following cell separation, unstimulated cells were cultured 
in growth medium for 24 hours. T N Fa levels in resultant supernatants were analysed by 
ELISA.
PsA SF MCs produce significantly more T N Fa than matched PBMCs (p <0.05). Normal 
PBMCs produce lower levels o f TN Fa than PsA PBMCs (Figure 4.8).
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Figure 4.7 TNFa mRNA expression in PsA SF cells
RT-PCR was performed to detect TNFa mRNA in PsA SF cells. Lanes 1-7 - representative i
of PsA patients, lane 8-positive control, lane 9- negative control 9 (dH20 + reagents). The .i
presence of cDNA was confirmed initially by detecting p Actin in the samples.
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Figure 4.8 TNFa production by PB and SF MCs
Matched SF and PB were obtained from patients with active PsA. PB from a normal 
control was obtained for comparison. Following 24 hours incubation supernatants were 
measured for TNFa content by ELISA. Data are mean ± s.e.m.of triplicate assay 
representative of 3 separate experiments.
(* p <0.05, Mann-Whitney).
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4.5 Discussion
The expression o f CD3^ cells in PsA SM and involved skin support existing data that PsA 
is a T cell mediated disease. The search for specific T cell clones has been elusive although 
similar clonal expansion of CD8+ T cells suggests that there is a response to a limited 
group o f antigens (Costello, Winchester et al. 2001). Until such antigens are characterised, 
attention has focused on the dysregulation o f the immune system following antigenic 
activation. As such, the phenotype and regulation of T cell responses following antigen 
stimulation may offer hope of finding novel therapeutic targets in PsA.
The characterisation of the T cell response in PsA has been inferred from the detection of 
elevated levels o f Thl cytokines in SF and SM compartments compared with RA and OA 
(Partsch, Steiner et al. 1997) (Ritchlin, Haas-Smith et al. 1998). Recent controversy 
however has arisen regarding the magnitude of Thl responses in the seronegative 
artln'opathies including PsA compared with RA (Canete, Martinez et al. 2000) hence 
clarification o f this issue is required.
The detection o f IFNy in inflammatory lesions has previously been difficult to quantify, as 
levels are often low in SF possibly as a result o f degradation by proteases or inadequate 
technology. The double antibody technique employed here to detect spontaneous IFNy 
secretion is a major advance in the characterisation of Thl responses as it permits detection 
of IFNy secreting cells without prior mitogen stimulation.
IFNy mRNA was readily identified using quantitative PCR in SF, SM and involved skin. 
Thereafter Thl cells were characterised by spontaneous IFNy secretion in SF compared 
with PB o f greater magnitude in PsA than in RA.
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These observations coupled with expression o f T hl specific cell surface markers CCR5 
and IL-18R support the hypothesis that T cell responses in PsA are o f Thl phenotype.
IFNy is known to stimulate TN Fa production and is capable o f inducing psoriasis and 
synovitis when administered subcutaneously for the treatment o f cutaneous diseases. As 
such IFNy can be implicated as a pro inflammatory cytokine upstream of TNFa. The use 
o f TN Fa blocking agents has already been identified as a therapeutic target in PsA and 
psoriasis. Determining those factors that regulate the immune response upstream of 
TN Fa and IFNy expression may offer novel strategies to inhibit inflammation. I therefore 
proceeded to explore those factors that regulate the Thl responses in PsA.
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Chapter 5 Expression of T hl regulatory cytokines in PsA synovium
The foregoing studies confmn the presence o f activated T cells in PsA SF, SM and 
psoriatic dermis and epidermis in our cohort. Spontaneous IFNy secretion and CCR5/IL- 
18R expression clearly indicate a predominant T hl response with the potential o f driving 
inflammation via the induction of TN Fa. Numerous mechanisms could promote and 
sustain Thl responses in PsA. The type and dose of antigen, host genetic background and 
ambient cytokine milieu are of particular relevance. The aim of this study was to identify 
expression o f cytokines in PsA that drive T hl responses, namely IL-12 and IL-18.
IL-18 expression has been demonstrated by a variety o f cells including macrophages, 
dendritic cells, kératinocytes, osteoblasts and synovial fibroblasts. Previous studies have 
identified the expression and functional importance o f IL-18 in rheumatoid arthritis 
synovial tissues (Gracie, Forsey et al. 1999) and murine arthiitis model systems (Wei, 
Leung et al. 2001). Furthermore, cutaneous expression of IL-18 by basal kératinocytes is 
markedly upregulated in psoriatic skin (Naik, Cannon et al. 1999). Despite these previous 
important obseiTations implicating IL-18 as a relevant cytokine in inflammatory arthritis 
and psoriasis, the expression o f IL-18 in PsA has not previously been described. IL-12 is a 
Thl promoting cytokine detectable in rheumatoid and osteoarthritic SMs (Sakkas, 
Johanson et ai. 1998). In psoriasis increased protein dermal expression in association with 
dendritic cells, macrophages and nerve endings has been described (Turka, Goodman et al. 
1995). Enhanced IL-12 p40 niRNA has been detected in lesional psoriatic skin as 
compared with normal and non-lesional psoriatic skin (Yawalkar, Limat et al. 1996). 
Furthermore, immunoreactivity for IL-12 p70 is markedly increased in psoriatic skin 
lesions predominantly expressed on MCs in the dermis (Yawalkar, Karlen et al. 1998).
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The aim o f this chapter was therefore to identify the expression and functional implication 
o f IL-12 and IL-18 expression in PsA synovium.
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5.1 IL-18 expression in PsA
5.1.1 Expression of IL-18 mRNA in PsA SM, skin, SF and PBMC.
I first sought evidence o f IL-18 expression at the mRNA level. Quantitative TaqMan PCR 
was performed using RNA obtained from PBMCs, SF cells, involved psoriatic skin and 
inflamed SM, all obtained from PsA patients. Successful RT PCR was confirmed by 
elucidation of p-actin with ethidium bromide on gel electrophoresis following standard 
RT-PCR (Figure 5.1). There was significantly higher expression o f IL-18 mRNA in PsA 
SF cells compared with matched PBMCs (Figure 5.2). O f interest however, although IL-18 
mRNA was easily detected in the SM, this was at a lower level than that detected in dermis 
(Figure 5.2; p<0.05, Mann-Whitney).
5.1.2 IL-18 expression in PsA SF and serum
I next determined IL-18 protein in SF and serum from PsA patients. Sandwich ELISA was 
employed to detect pro and mature IL-18 in PsA SF and serum (Diaclone, France). SFs and 
matched serum were collected from patients with active PsA undergoing needle 
artlii'oscopy. In a subset o f patients, fluid alone was obtained at needle aspirate at the time 
of intra-aiticular steroid injection as clinically indicated. Samples were spun free o f cells 
and stored at -20°C  until assay. Storage had no effect on subsequent cytokine detection 
(Gracie and Mclmies personal communication). IL-18 was detected in all SF samples 
(Figure 5.3) at concentrations ranging from 18-1200pg/ml (median 172pg/ml). In contrast,
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matched serum had low or undetectable levels (SF vs. serum: p<0.05). These levels are 
comparable to those found in RA serum and SF (Gracie, Forsey et al. 1999) and strongly 
suggest that local production of IL-18 explains the SF levels detected.
SM PsA skin PsA SF
Figure 5.1 RT-PCR for p actin in PsA synovial tissue and fluids
RT-PCR was performed to detect P-actin in PsA PBMCs, SF cells, SM and involved 
psoriatic skin. Confirmation of the presence of P-actin was required prior to subsequent 
quantification of IL-18 mRNA expression by TaqMan PCR. Lanes 1-8 representative SM, 
lane 10-14 involved psoriatic skin, lane 16-19-SF, lane 20- negative control (dH20 + 
reagents).
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Figure 5.2 IL-18mRNA expression in PsA tissue and cell samples
Quantitative PCR (TaqMan) determined the level of human IL-18 mRNA expression in 
PsA SM, involved psoriatic skin, SF and PBMCs. Median levels of IL-18mRNA expressed 
as a percentage of HPRT are shown. n= numbers of samples analysed. Significantly higher 
levels of IL-18mRNA are found in SF compared with PB and in psoriatic skin compared 
with membrane. (* p<0.005 Mann-Whitney)
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Figure 5.3 IL-18 protein expression in PsA SF and serum
Serum and SFs were collected from patients with active PsA. ELISA with sensitivity 
ranging of 62.5pg/ml and range up to 2000pg/ml was used to determine IL-18 levels. 
Levels in PsA SFs were significantly higher than in 6 versus 13 serum samples.
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5.1.3 Distribution of IL-18 expression in psoriatic synovium and skin
I next sought the tissue origin and localisation o f IL-18 in PsA involved skin and SM. 
Previous studies in this area have elucidated lining layer and interstitial expression of IL- 
18 by macrophages and fibroblast like synoviocytes in RA synovial tissue (Gracie, Forsey 
et al. 1999). It was o f  interest therefore to compare and contrast this expression pattern 
with that in PsA. To investigate the presence of IL-18 in PsA SM and skin, paraffin 
embedded sections o f appropriate tissues were stained with murine monoclonal anti-IL-18 
(E3E1). Positive staining was effectively neutralised by prior incubation o f the antibody 
for 1 hour at 37^C with 100 ng/ml rIL-18. Moreover in previous studies (Gracie, Forsey et 
al. 1999) the staining obtained with E3E1 was shown to be identical to that obtained with a 
broad panel of monoclonal antibodies kindly donated by Dr A Jackson (Leeds). Tonsil was 
used as a positive control (Figure 5.4). It is likely therefore that the staining specificity 
obsei*ved is properly representative o f tissue IL-18 expression.
The following figures demonstrate the tissue distribution o f IL-18 binding in PsA 
synovium (Figure 5.5) and skin (Figure 5.7). IL-18 expression was present in all tissues 
examined. The distribution of IL-18 was characterised by semi-quantitative measurement 
o f expression in different tissue compartments. IL-18 was most prominent within and 
adjacent to lymphoid aggregates in SM, similar to the pattern o f expression found in tonsil. 
IL-18 was also detected however in lining layer and in sublining interstitial areas, although 
cell numbers in these areas were lower (Table 5.1). Several cell lineages have been shown 
capable of IL-18 expression, including macrophages, endothelial cells, and synovial 
fibroblasts. Since macrophages were the most likely predominant cell subset with IL-18 
expression, parallel sections were stained with monoclonal antibodies to CD68 and to IL-
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18. IL-18 co-expressed with CD68^ macrophages predominantly in the lining layer in SM 
(Figure 5.6).
For comparative purposes, IL-18 expression in psoriatic skin lesions was characterised 
using E3E1. Figure 5.7 demonstrates predominant staining in the epidermis, with broad 
expression throughout the kératinocytes in both the basal layer and in superficial areas. In 
the dermis, co-expression was found predominantly in CD68+ macrophages (Figure 5.6). 
Finally, IL-18 expression was compared in matched biopsies obtained from synovium and 
skin of PsA patients. Data shown in table 5.2 demonstrate the predominant expression in 
kératinocytes that exceeds that observed in other inflamed tissues. These data are 
commensurate with the higher levels o f IL-18 mRNA detected in skin as compared with 
synovium (Figure 5.2).
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Figure 5.4 IL-18 expression in human tonsil.
Paraffin embedded sections were stained with anti IL-18 antibody (E3E1). Primaiy 
antibody was detected with biotinyiated goat anti mouse IgG using the avidin/biotin 
complex immunoperoxidase method. Colour development was achieved using 
diaminobenzidine. A, tonsil positive control B, tonsil negative control (Magnification x20).
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Figure 5.5 IL-18 expression in psoriatic SM.
Immunohistochemical analysis o f SM from a representative PsA patient. Paraffin 
embedded sections were stained with H&E (A) anti IL-18 antibody (E3E1) (B) as 
described in legend figure 5.4. (Magnification x20).
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LL SL LA
PsA l 3 0 1
PsA2 3 0 1
PsA3 2 0 N/A
PsA4 0 0 2
PsA5 3 0 N/A
Table 5.1 Distribution pattern of IL-18 expression in PsA synovial tissues
Quantitative expression of IL-18 was assessed in synovial tissue lining layer (LL), sub 
lining layer (SL) and lymphoid aggregates if  present (LA). A scoring system agreed 
between 2 independent observers was employed. 0 = no staining, 1= 1-10% of nucleated 
cells stained positive, 2=10-25% nucleated cells, 3=25-50% and 4=>50% positive. N/A, no 
aggregates present.
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Figure 5.6 IL-18 expression in CD68 macrophages
Double staining o f PsA SM is shown from a representative PsA patient. IL-18 was 
detected immunochemically using anti IL-18 antibody E3E1 and developed with 
diaminobenzidine (brown). Macrophages were then stained with anti-CD68 and developed 
using Vector SG (grey). Magnification x20. Double positive cells are shown by arrows.
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Figure 5.7 IL-18 expression in involved psoriatic skin.
Immunohistochemical analysis o f involved skin from a representative PsA patient. Paraffin 
embedded sections were stained with anti IL-18 antibody (E3E1). Primary antibody was 
detected with biotinyiated goat anti mouse IgG using the avidin/biotin complex 
immunoperoxidase method. Colour development was achieved using diaminobenzidine. A, 
psoriatic skin H&E; B, Psoriatic skin with anti IL-18; (Magnification x20)
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Epidermis Subdermis Synovial membrane
CD68 IL-18 CD68 IL-18 CD68 IL-18
PsA 1 0 4 2 1 2 3
PsA 2 0 4 1 1 2 3
PsA 3 0 4 3 2 3 1
PsA 4 0 4 2 1 2 2
Table 5.2 IL-18 and CD68 co-localisation in psoriatic skin and SM
Quantitative expression o f IL-18 and CD68 was assessed in matched skin / synovial tissue 
pairs (n=4) using a scoring system agreed between 2 independent observers. 0 = no 
staining, 1= 1-10% of nucleated cells stained positive, 2=10-25% nucleated cells, 3=25- 
50% and 4=>50% positive.
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5.1.4 SM and skin secrete IL-18
Finally, I investigated whether SM and skin released IL-18 in vitro. To this end I 
established a novel synovial biopsy explant culture system. Freshly isolated SM and 
involved psoriatic skin was obtained at needle arthroscopy and skin biopsy respectively. 
Tissue was gently disggregated with a 190 needle, then immediately transferred to culture 
medium and cultured for 72 hours in vitro without exogenous stimulation. Subsequent 
supernantants were assayed for the presence of IL-18 by ELISA. SM and skin explant 
cultures produced median 2910 pg/ml and 8799 pg/ml IL-18 respectively (figure 5.8). 
These data confirmed that IL-18 expression detected at mRNA level in tissue was reflected 
in endogenous secretory activity ex vivo.
5.1.5 IL-18 release via Benzyl ATP dependant pathway
Elucidation of the mechanisms whereby cytokines are released from cells may offer further 
potential to inhibit cytokine-mediated inflammation. It is already well established that the 
rapid release o f IL -ip  requires ATP and is a receptor-mediated event. ATP receptors such 
as P2X-7 are found on many cells including monocytes and macrophages. When triggered 
by ATP, the cell membrane becomes transiently porous with loss o f membrane electrical 
potential. Triggering o f the P2X-7 is specific for the release o f mature IL -ip  and release of 
IL-18 in LPS-stimulated whole blood cultures (Perregaux, M cNiff et al. 2000). 
Furthermore, antagonists to P2X7 result in reduced IL-18 and IL -lp  release from LPS- 
treated human macrophages (Ferrari, Chiozzi et al. 1997). We therefore sought to 
determine whether IL-18 release as observed in PsA tissue cultures is ATP dependent.
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To determine optimal experimental conditions, SF MCs were stimulated with LPS at 
concentrations of 10pg/ml and lOOpg/ml for 1 or 2 hours. Secretion of IL -ip  following 
the addition o f benzyl ATP for 20 minutes was assessed in culture supernatants by ELISA. 
Optimal IL -ip  expression was observed following 2 hours incubation with LPS 10pg/ml 
(971 pg/ml). Further stimulation with LPS at lOOpg/ml resulted in no further IL -lp  
expression in the presence of Benzyl ATP (608pg/ml) (Figure 5.9).
Having identified 2 hours was optimal time for LPS stimulation; single cell adherent 
suspensions were cultured at 2 x l0 ‘^ /ml in the presence o f 2 different concentrations o f LPS 
(lOpg/ml o f lOOpg/ml). Fresh culture medium was added with or without benzyl ATP and 
resultant supernatants were assayed for the presence o f IL-18 by ELISA.
IL-18 levels in SF cell supernatants were generally low despite stimulation with LPS 
10pg/ml and lOOpg/ml. The addition o f Benzyl ATP to SF cells stimulated with LPS at 
both concentrations for 2 hours resulted in an increase o f IL-18 production (Figure 5.10).
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Figure 5.8 IL-18 production by psoriatic skin and SM ex vivo
Lesional psoriatic skin and SM were obtained from patients by elliptical skin biopsy and 
needle arthroscopy respectively. Tissue was disaggregated with a 19G needle and 
subsequently cultured without exogenous stimulation for 72 hours. IL-18 levels in resultant 
supernatants were measured by ELISA.
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Figure 5.9 Benzyl ATP release of IL-ip from LPS stimulated PsA SF MCs
PsA SF cells were cultured in the presence o f LPS at concentration o f 10pg/ml and 
lOOpg/ml for 1 hour (A) or 2 hours (B). Supernatants were removed after 1 and 2 hours 
then replaced with fresh culture medium plus or minus the addition o f Benzyl ATP. 
Supernatants were then harvested after 20minutes and assessed for IL -ip  secretion by 
ELISA.
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Figure 5.10 IL-18 release from LPS activated PsA SF MCs with Benzyl ATP
Benzyl ATP was added to cultures containing SF MCs stimulated with LPS at lOmg/ml 
and lOOmg/ml for 2 hours. Supernatants were harvested after 20 minutes for detection of 
IL-18 by ELISA.
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5.2 IL-12 expression in PsA
We have previously shown that IL-18 can drive Thl and Th2 responses depending on host 
genetic background and ambient cytokine milieu (Xu, Chan et al. 1998). Therefore the 
defining cytokine functional phenotype may depend not primarily upon IL-18 expression 
but upon the context o f such expression. IL-12 is critical to this process since IL-12 in 
synergy with IL-18 drives Thl responses in vivo (Okamura, Kashiwamura et al. 1998). 
Increased levels o f IL-12p70 have been described in PsA SFs (Spadaro, Rinaldi et al. 
2002). I therefore defined IL-12 expression in PsA tissues, which had not previously been 
described. Parallel studies performed by our collaborators (Dr David Kane and colleagues, 
Dublin) have identified the presence of IL-12 mRNA in PsA SM samples.
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5.2.1 IL-12 p70 and IL-12 p40 expression in PsA SF and serum
To determine SF and serum levels o f total IL-12 p40 and o f IL-12 p70 heterodimers, 
sandwich ELISA was performed. Serum and SFs were obtained from patients with active 
PsA disease at the time o f needle arthroscopy or joint injection as clinically indicated. 
ELISA detected elevated levels o f IL-12 p40 up to 334pg/ml in SFs in 11 patients with 
active PsA. Matched serum was available in 5 patients that was found to contain 
comparable levels ranging from 25pg/ml to 94pg/ml (SF vs. serum: p=0.3). The median 
concentration o f IL-12 p40 in SF was 45pg/ml and 40pg/ml in serum (Figure 5.11).
IL-12 p70 levels were also detected in SF from PsA patients (Figure 5.12), whereas lower 
levels were detected in SF from RA patients with active disease prior to commencement of 
DMARD administration (gift o f Dr D Porter, TIC ORA study sera). Surprisingly however 
IL-12p70 expression was detected in serum from normal, healthy volunteers at higher 
levels. This experiment was repeated with identical results to confirm the levels detected. 
The significance o f this is not clear but could reflect consumption o f IL-12p70 in actively 
inflamed patients leading to spuriously low levels detectable as free cytokine as compared 
to ‘noil-inflamed’ healthy volunteers.
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5.2.2 IL-12 expression in PsA SM
I next determined the pattern o f tissue expression o f IL-12 in PsA SM and skin. Paraffin 
embedded tissue sections were stained with murine monoclonal anti IL-12 p35 (kindly gift 
o f Dr S Porcelli, Wistar Institiute, Philidelphia). Figure 5.13 demonstrates tissue 
expression o f IL-12p35 in PsA SM and skin. IL-12 p35 subunit was detected in all SM and 
skin sections examined (n=6). In SM, staining was found predominantly in the sub-lining 
layer, with few lining layer cells found to contain IL-12. In skin sections, IL-12 p35 was 
expressed by kératinocytes in the epidermis. There was additional expression in the dermis 
but to a lesser degree. Serial sections were subsequently stained for the expression o f IL- 
12p70 using IL-12p70 monoclonal antibody (R&D clone 24945.11). No positive staining 
was detected using this antibody in SM or skin sections. Thus, the epitope on the IL-12 
p40/p35 heterodimer that is expressed and amenable to antibody binding in tissue, may be 
differentially detected by discrete monoclonal antibody clones. It is also possible that p35 
could be present as part o f a novel cytokine complex with other homologues o f the IL-12 
family e.g. IL-27, EBI3, thereby yielding signal without concomitant IL-12p70 detection 
(Pflanz, Timans et ai. 2002; Brombacher, Kastelein et al. 2003).
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Figure 5.11 IL-12 p40 expression in PsA serum and SF
Serum and SFs from patients with active PsA were obtained and assayed for the presence 
o f IL-12p40 by ELISA. Levels in SFs were higher than serum however this did not reach 
statistical significance (p=0.3, Mann Whitney)
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Figure 5.12 IL-12 p70 expression in PsA serum and SF
SF was obtained from patients with active PsA (n=19) and RA (n=20). Sera were similarly 
obtained from RA (n=20) and normal individuals (n=19) for comparison. IL-12p70 levels 
were analysed by ELISA.
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Figure 5.13 EL 12 p35 expression in PsA SM and skin
Immunohistochemical analysis of skin (A) and synovial tissue (B) from a representative 
PsA patient. Paraffin embedded sections were fixed in acetone and stained with anti IL- 
12p35 (clone C7.4). Primary antibodies were detected using biotinylated goat anti mouse 
IgG then with streptavidin-alkaline phophatase complex and diaminobenzidine. A, PsA 
skin and B, PsA SM. (Magnification x 20)
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5.3 Discussion
This study clearly demonstrates the presence o f regulatory cytokines lL-18 and IL-12 in 
psoriatic SM, skin and SFs. IL-18 and IL-12 are critical regulators o f Thl responses. The 
detection o f IL-12 and IL-18 in this context provides a possible mechanism for the 
predominant Thl responses indicated in the previous studies.
The expression o f IL-18 mRNA in PsA SF and membrane is a novel observation. This 
study revealed markedly up regulated cutaneous IL-18 mRNA expression in involved skin 
commensurate with previous studies indicating that human kératinocytes constitutively 
express IL-18 and secrete IL-18 after treatment with pro-inflammatory mediators (Naik, 
Cannon et al. 1999).
Variable levels o f IL-18 were detected in PsA SF compared with absence o f cytokine in 
matched sera. This finding contrasts with those in RA where levels o f IL -18 were detected 
in one third o f serum samples (Grade, Forsey et al. 1999). SM was the likely source of IL- 
18 as it was present in synovial cultures and could be predominantly localised 
immunohistochemically to the synovial lining layer. The release o f IL-18 appeared to be 
benzyl ATP dependant as LPS stimulation in the presence o f benzyl ATP resulted in a 
significant increase in cytokine detection. This observation confirms previous studies that 
indicate release o f both IL -lp  and IL-18 are ATP dependant. Such observations have 
clinical implications as IL-1|3 and IL-18 release can be completely blocked using a P2X7 
receptor antagonist. There is clearly the possibility that IL-18 levels detected in synovial 
culture may represent release o f stored cytokine and further experiments are required to 
determine whether IL-18 inliibitors can reduce synthesis in vitro.
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IL-18 expression in SM and skin was localised to the lining layer and kératinocytes 
respectively. Other pro inflammatory cytokines such as IL-1, IL-6 TN Fa that are abundant 
in synovial tissue are similarly localised to the synovial lining layer where they are 
predominantly macrophage derived. The intensity of lining layer cells that expressed IL-18 
and the double staining with CD68+ cells make it likely that macrophages contribute to the 
synovial production o f IL-18 in PsA. However IL-18 is expressed by a wide variety of 
cells and further localisation o f cellular expression using dual staining is required.
The biological profile o f IL-18 in RA and animal models implicates it as a key pro 
inflammatory cytokine in other inflammatory autoimmune diseases such as psoriasis and 
PsA. Localised expression o f IL-18 by SM in this study may have implications for mode 
o f delivery o f IL-18 targeted therapies.
Although IL-18 is capable o f promoting synovial inflammation independently of IL-12, co 
administration of IL-12 and IL-18 promote more severe disease in animal models of 
arthritis (Leung, Mclnnes et al. 2000). Transient gene transfer for IL-12 in animal models 
accelerated disease progression and increased severity of arthritis (Parks, Stricter et al. 
1998). Neutralisation o f IL-12 resulted in delayed disease onset and attenuation of disease. 
Fuflhermore, IL-12, independent of IFNy, is able to induce pathogenic, inflammatory T 
cells that are able to induce psoriasis in mice (Hong, Chu et al. 1999). The expression of 
IL-12 was therefore a logical progression to place IL-18 expression in context. IL-12 
induces IFNy via up regulation o f IL-18R. Studies in chapter 4 demonstrated IL-18R 
expression on PsA SF cells suggesting that this mechanism may be occurring within the 
synovial compartment.
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IL-12 p35 staining was detected in all membrane and skin samples analysed. Higher levels 
o f IL-12 p40 subunit protein were detected in the SF compared with matched serum 
suggesting local production o f cytokine. The high levels o f IL-12p70 in normal serum 
compared with SF and serum of patients with inflammatory arthritis is unexpected. The 
emerging biology o f IL-12 may explain some o f the findings in this study. On activation, 
heterodimeric IL-12 is found in small amounts, whereas free p40 is produced in excess. 
Besides IL-12, other p40-dependent molecules exist that orchestrate Thl responses. 
Homodimeric p40 can act as an IL-12 antagonist by competing for its receptor. Recent data 
also reveal potential immunostimulatory functions of p40. In addition, p40 can be 
covalently linked to a p35-related protein p i 9. This heterodimer is known as IL-23, a novel 
cytokine, that has activities on memory T cells. Finally, IL-27 is a heterodimer composed 
o f the p40-related protein EBI3 (Epstein-Barr virus-induced gene 3) and the p3 5-related 
protein p28. IL-27 is involved in early Thl initiation (Brombacher, Kastelein et al. 2003).
Having previously defined that PsA is a Thl mediated disease and that regulatory 
cytokines such as IL-12 and IL-18 are expressed in SM and fluid, it was therefore crucial 
to determine the functional significance o f such cytokine expression.
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Chapter 6 Regulation of Thl responses in PsA
A critical aspect o f host immune defence against infection is mediated via the effector 
function of Th cells. Following antigen presentation, Th cells differentiate into 
functionally distinct subsets characterised on the basis o f their effector cytokine release 
(chapter 1). Most immune responses involve contributions from both Thl and Tli2 cells 
that cross regulate effector functions - a balance between T hl and Th2 cytokine could 
therefore determine whether responses are appropriate or detrimental 
(immunopathogenesis).
The differentiation o f T hl and Th2 responses from precursor Th cells (Thp) depends on a 
variety o f complex developmental processes including dose o f antigen, density o f the 
antigen peptide; MHC complex, co stimulation, genetic background and critically the 
ambient cytokine milieu. In chapter 4 I demonstrated some evidence for the presence of 
T hl cells that were activated and differentiated in vivo in PsA. Thereafter in chapter 5 I 
have demonstrated the presence o f cytokines IL-12 and IL-18 that are known to promote 
the development o f Thl cells. However to confirm that these phenomena are functionally 
linked it was important to test the activities ex vivo o f IL-12 and IL-18 in PsA derived cell 
lineages. To this end, I have utilised PsA PB and SF derived cell cultures to measure the 
effector activity o f IL-12 and IL-18 in the context o f plausible Thl mediated function. The 
aim o f this chapter was therefore to determine the functional effects of regulatory 
cytokines in vitro thereby placing IL-12, IL-18 and IFNy expression in context. 
Preliminary data exploring intracellular signalling and cytokine release mechanisms are 
described.
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6.1 Effects of CD3, CD28 and cytokines on PsA SF MC proliferation
Optimal T cell activation requires the presence of a co-stimulatory signal that may be 
generated via the interaction between CD80/CD86 on the AFC and CD28 expressed on the 
T cell. To confirm that SF MCs were activated by this mechanism, proliferation in 
response to anti-CD3 (plastic adherent) /anti-CD28 (soluble) stimulation in the presence of 
the iimate cytokines IL-12 and IL-18 was determined using ^H-thymidine incorporation 
assays. IL-15 was added in addition as a further positive control (Mclnnes, al-Mughales et 
al. 1996). Cytokine concentrations were derived from previously published experiments in 
the laboratory that showed synergistic effects on RA derived synovial cultures (Grade, 
Forsey et al. 1999). Proliferation was significantly increased by the addition of anti-CD3 / 
anti-CD28 in comparison to resting cultures (p <0.05, Mann Whitney). However, the 
addition of recombinant cytokine IL-12, IL-15 or IL-18 had no additional effect on 
proliferation (Figure 6.1). Since IL-15 has previously been shown to induce high levels of 
RA and PsA SF lymphocyte proliferation in isolation, this suggested that the mitogen 
antibody cocktail employed had induced maximal proliferative responses that were 
unlikely to be further enhanced by cytokine addition.
6.2 Synergistic effect of IL-12 and IL-18 in IFNy production by PsA SF cells
Although no additional response was measured in terms of proliferation, it remained 
possible that alterations in cytokine output could occur. Anti-CD3 / anti-CD28 stimulated 
SF cells were therefore cultured with IL-12 and IL-18 alone or in combination for 24 hours 
as before and cytokine release was measured by ELISA. Addition o f IL-18 alone induced
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minimal IFNy release. In contrast, and commensurate with previous observations in 
human T cell clones (Aim, Maruo et al. 1997), IL-12 was able to induce IFNy release. 
Addition of IL-18 together with IL-12 led to further enhancement o f IFNy release 
suggesting a cooperative / synergistic role for IL-18 in Thl effector function (Figure 6.2).
6.3 Effect of IL-12 and IL-18 on TNFa production
The observation that more T cells in PsA than in RA synovium were IFNy positive 
(chapter 4) suggested that IFNy could play a distinct role in TN Fa regulation in PsA. 
TN Fa release in the above culture system was therefore examined to determine whether 
IL-12 and IL-18 provoked similar TN Fa secretion patterns. Anti-CD3 / anti-CD28 
induced basal TN Fa expression that was higher in SF MCs than in PB MCs (252pg/ml vs. 
46pg/ml; Figure 6.3). Unlike IL-12, IL-18 could promote TN Fa release in PB cultures. 
(IFNy release is not easily detected in primary PB cultures and was not performed in these 
experiments (Gracie, Forsey et al. 1999). Both IL-12 and IL-18 induced significant 
increases in TN Fa production by SF MCs (p<0.05, Mann Whitney). However IL-18 
induced significantly higher levels o f TN Fa release than IL-12. There was no synergistic 
induction o f TN Fa in PBMCs with IL-12 and IL-18 combined. Since these cultures did not 
contain measurable IFNy (Figure 6.2) it is probable that IL-18 was operating via an 
alternative pathway. To test this formally a neutralising anti-IFNy antibody would be 
required -  unfortunately this was not available at the time o f performing these experiments. 
As a further control, no significant increase in TN Fa production was detected by SF MCs
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cultured with IL-15 alone (Figure 6.3) suggesting that the effects noted above might be 
specific to given innate cytokine subsets.
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Figure 6.1 SF cell proliferation with anti-CD3 and anti-CD28
PsA SF MCs were cultured for 24 hours with recombinant cytokines IL-12 (Ing/ml), IL-18 
(lOOng/ml), IL-15 (Ing/ml) and ^H-thymidine incorporation was measured over the last 6 
hours of culture. Data shown are mean ± s.e.m of triplicate culture. (*P<0.05, Mann 
Whitney). Data shown are representative of 4 similar experiments.
157
3500
3000
2500
i  2000 &£  1500 
1000 
500 
0
cells alone IL-12 IL-18 IL12/18
Figure 6.2 IL-12 and IL-18 induction of IFNy by PsA SF cells
PsA derived SF cells activated with anti-CD3 and anti-CD28 antibody were cultured in the 
presence of IL-12 and IL-18 alone or in combination for 24hours. Concentration of IFNy 
was measured by ELISA. There was significant increase in IFNy secretion in cells 
stimulated with IL-12 alone that was further increased by addition of IL-18 (*P<0.05, 
Mann Whitney). Data are representative of 5 patients in which similar results were 
obtained. Data expressed as mean ± s.e.m of triplicate cultures.
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Figure 6.3 Effect of innate cytokines on production of TNFa
Matched PB and SF MCs were obtained from patients with active PsA. Cells activated 
with anti-CD3 and anti-CD28 antibody were cultured in the presence o f recombinant 
cytokine for 24 hours. Levels o f TN Fa were measured in supernatants by ELISA. 
(*P<0.05, Mann Whitney SF alone vs. SF with IL-12 or IL-18). Data shown mean ± s.e.m. 
o f triplicate cultures and are representative o f 5 similar experiments obtained from 
individual patients.
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6.4 Presence and Functional role of Natural Killer T cells in PsA
The primary objective in my studies was to investigate effector Thl cell responses in PsA. 
The stimulatory responses demonstrated thus far were dependent on the presence o f anti- 
CD3 suggesting that T cells may be the source of resultant IFNy or TN Fa production. 
However, a further possibility was that CD3^ NKT cells might in some way contribute to 
the cytokine release detected in the above assay system. Activated NK T cells can produce 
variable amounts o f IL-4 and IFNy depending on the ambient cytokine milieu making 
them directly relevant in determining Thl/Th2 responses in human disease states (Hafner, 
Falk et al. 1999). Moreover, a pathogenic role for NK T cells has been implicated in 
animal studies of psoriasis (Nickoloff, Bonish et al. 2000).
6.4.1 Presence of NKT cells in PsA synovium
I thereafter sought NK T cells in PsA SF compared with matched peripheral blood. PB and 
SF MCs were obtained from patients with active PsA. NK T cells were identified using 
an ti-V pil and anti-CD3 by FACS analysis. CD3/TCR V p i l  double positive cells were 
identified in both synovial and PB compartments (Figure. 6.4). O f interest there was no 
difference in the relative expression in each compartment, in contrast to previous studies in 
RA (Yanagihara, Shiozawa et al. 1999). This suggested that there was no particular 
selection or accumulation of NK T cells in the synovium, or less likely that recruited NK T 
cells altered their characteristic phenotype upon tissue entry.
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6.4.2 Effect of a  galactosyl ceramide on PsA SF and PB MC proliferation
Since these data suggested that NKT cells are indeed present in synovium, I investigated 
their functional significance. Glycosylceramides, particularly agalcer, presented by CD Id 
molecules on AFC are native NKT ligands that promote subsequent effector function. I 
sought to determine whether PB or SF NK T cells proliferated to agalcer. Basal 
proliferation by SF cells was greater than in PB cells. The addition o f a  galcer, either alone 
or in the presence of IL-15 (a critical NK cell activating factor used as control) or IL-18 
did not significantly increase proliferation o f either PB or SF MCs (Figure 6.5)
6.4.3 IFNy and TNFa production by PsA SFC in response to a  galcer and 
recombinant cytokines
I next measured expression o f TN Fa and IFNy following addition o f agalcer to SF MCs in 
the presence o f IL-12, IL-15 and IL-18. DMSO was added as a diluent control to a similar 
final concentration. In no cultures was I able to measure any IFNy. Although SF MCs 
produced variable amounts o f T N Fa in response to individual cytokines, no significant 
increase of TN Fa was observed with the addition of agalcer. These observations strongly 
suggested that NKT cells when stimulated with their native TCR ligand were not 
substantial contributors to the IFNy and TN Fa expression reported above. Future studies 
will be required to determine the wider expression profile o f NKT cells following 
stimulation since this would likely include Th2 cytokines such as IL-4. Since the latter is
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not detected in PsA synovium there was no obvious rationale for pursuing such 
experiments in the context o f my studies.
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Figure 6.4 NKT cell expression in PsA PBMC and SFC
Matched PBMC and SF MCs were obtained by Ficol-hypaque separation Cells were 
stained with FITC conjugated anti-CD3 antibody and PE conjugated TCR V pl 1 antibody. 
Gating on forward and side scatter identified lymphocyte population. Percentage o f cells 
with positive staining for CD3 and V p i l  are shown above. There was no significant 
increase in double positive cells in SF compared with PB. Data are representative o f 3 
different patients.
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Figure 6.5 SF and PB MC proliferation in response to a  galcer
Matched SF and PB MCs were cultured for 24 hours with recombinant cytokines and 
thymidine incorporation over the last 6 hours. Although an increase was detected in the IL- 
15 stimulated cells in both compartments, there was no additional increase in proliferation 
in the presence o f agalcer. Values shown are mean ± s.e.m. o f triplicate cultures. Data are 
representative o f 5 individual experiments.
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Figure 6.6 TNFa production by PsA synovial MCs in response to agalcer
SF MCs were cultured with recombinant cytokines with or without agalcer for 24 hours. 
Resultant supernatants were assessed for TN Fa by ELISA. No increase in TN Fa 
production was detected with addition o f agalcer. Data are representative o f three patients 
and are mean s.e.m. o f triplicate cultures.
165
6.5 Functional role of p38 mitogen activated protein kinase in PsA
The forgoing experiments clearly indicate that IL-12 and IL-18 were capable of promoting 
IFNy release from T cell subsets in PsA synovium. I next performed preliminary studies to 
explore possible signal pathways involved in such expression. These were intended to 
pump prime future detailed investigations. Previous studies indicate that IFNy expression 
by activated Thl cells is MAP kinase dependant (Rincon, Enslen et al. 1998). Moreover 
IL-12 was shown to activate p38 MAPK activity via pathways independent o f stat-4 
phosphorylation (Zhang and Kaplan 2000). p38 MAPK may be an important in vivo 
therapeutic target. These published data suggest that p38 represents a logical point for 
initial studies and therefore 1 utilised SB 203580, a selective inhibitor for p38 MAP kinase 
in PsA PB and SF MC cultures.
PB and SF MCs were cultured with anti-CD3 / anti-CD28, together with recombinant IL- 
12 / IL-18 in combination with or without SB203580 for 24 hours. DMSO was used as a 
diluent control for SB203580. There was little production o f IFNy by SF MCs in the 
absence o f cytokine stimulation consistent with previous observations. SF MCs produced 
IFNy to IL-12 / IL-18 that was inhibited after the addition o f SB203580 (SB203580 vs. 
DMSO control; p<0.05) (Figure 6.7). Although clearly o f a preliminary nature these data 
provide an early indication that p38 dependent pathways may offer an opportunity to 
suppress Thl cell activation In PsA synovium.
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Figure 6.7 Effect of MAP kinase inhibitor on cytokine induced IFNy
SF MCs were obtained from patients with active PsA. Cells were cultured with anti-CD3 
and anti-CD28, together with recombinant cytokines IL-12 and IL-18 in the presence o f the 
specific p38MAP kinase inhibitor, SB 203580 or DMSO alone (as carrier diluent control). 
IFNy release into supernatants was assayed by ELISA. (* P <0.05, Mann Whitney). Data 
are representative o f three similar experiments from independent patients.
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6.6 Discussion
Having identified the presence o f  IL-12 and IL-18 in PsA SF and membrane, the functional 
significance o f these cytokines alone or in combination is demonstrated in these studies.
Proliferation of PsA synovial derived MCs was increased following anti-CD3 and anti- 
CD28 stimulation. No additional proliferation was observed by the addition of recombinant 
cytokines. Subsequent co culture experiments with IL-12 and IL-18 induced regulation of 
individual cell expression rather than simply an increase in cell numbers In subsequent 
experiments therefore, matched SF and PBMCs were stimulated with anti-CD3 and anti- 
CD28 in the presence o f cytokine to determine whether cytokines induced TN Fa and IFNy 
expression.
SF MCs spontaneously produce TN Fa compared with PB commensurate with previous 
studies. The addition o f IL-18 alone to SF MCs induced significant TN Fa production. 
There was no significant increase in SF MCs stimulated with recombinant IL-15. SF MCs 
produce significantly elevated levels o f IFNy after stimulation with IL-12 and IL-18 in 
combination compared with no cytokine stimulation or with IL-12 alone. SF cells alone 
even in the presence o f anti-CD3 and anti-CD28 produced no detectable IFNy suggesting 
that cytokine stimulation is necessary for IFNy secretion. Elucidation of possible 
mechanisms whereby cytokines induce T N Fa and IFNy was a logical progression from 
this work
The subsequent experiments in this chapter suggest that IL-18/IL-12 induces IFNy 
expression via at least MAP kinase dependant pathways.
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Although there is considerable evidence implicating NK T cells in the pathogenesis of 
psoriasis, the evidence for their role in PsA has not been studied. Given that PsA and 
psoriasis form a clinical spectrum o f one disease, it was logical to assume that NK T cells 
may have a pathogenic role in driving inflammation in PsA particulary as we observed a 
population o f NK T cells in the SF o f patients with active disease.
NK T cells are a potential source o f IFNy or IL-4 depending on the ambient cytokine 
milieu. I did not observe an increase in proliferation, TN Fa or IFNy production following 
stimulation with the synthetic glycolipid agalcer in the presence o f cytokines IL-12 or IL- 
18. These limited data do not support a functional role for NK T cells in PsA.
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Chapter 7 Expression and function of IL-17 in PsA
Previous studies focused largely on identifying those factors that may perpetuate synovial 
and cutaneous inflammation via T cell activation in PsA. Resultant joint damage in PsA is 
characterised by specific radiological changes that include both bone formation and 
resorption. This spectrum o f radiological patterns is as yet unexplained. Recent studies 
have indicated that IL-17, a Thl cell derived pro inflammatory cytokine, and IFNy may 
have opposing effects on osteoclastogenesis (Takayanagi, Ogasawara et al. 2000). Since I 
have initially demonstrated IFNy expression, I next sought to characterise IL-17 expression 
and functional activity.
Most data derived from T cell clones suggest that IL-17 is Thl predominant (Aarvak, 
Chabaud et al. 1999). IL-17 mediates effects in both leukocyte and stromal cell lineages. 
IL-17 can induce IL-6, IL-8, TN Fa and IL -ip  release by leukocytes. Other varied effects 
include stimulation o f PGE2 , inducible NOS and chemokine synthesis by leukocytes and 
fibroblasts. Direct and indirect effects on chondrocytes have been reported including up 
regulation o f matrix metalloproteinase expression (Cai, Yin et al, 2001). Finally, when 
incubated with osteoclast progenitor cells and osteoblasts, IL-17 induces 
osteoclastogenesis. (Kotake, Udagawa et al. 1999). IL-17 may therefore play an important 
upstream role in T cell mediated inflammation by stimulation o f stromal cells to promote 
local tissue remodelling and damage. IL-17 blockade results in suppression o f collagen- 
induced arthritis whereas over expression enhances disease. These deleterious effects on 
cartilage may function independently of IL -lp  as blocking IL-1 with neutralising peptide
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had no effect on IL-17 induced cartilage damage (Lubberts, Joosten et al. 2001) in vivo 
and in vitro.
IL-17 has been studied in a variety o f human models of inflammation. IL-17 is detected in 
RA SFs and membrane (Chabaud, Durand et al. 1999). In psoriasis, the majority of CD4H- 
and CD8+ T cell clones derived from lesional psoriatic skin express IL-17 mRNA 
compared with none in non lesional skin suggesting that IL-17 may be involved in the 
development o f cutaneous inflammation. IL-17 can directly promote keratinocyte secretion 
o f pro inflammatory cytokines (Tennissen, Koomen et al. 1998). Thus far, the presence 
and role o f IL-17 in PsA has not been studied.
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7.1 Expression of IL-17 in PsA SF and serum
I initially sought to determine IL-17 levels in serum and SFs o f patients with active PsA. 
SF and blood was collected at needle arthr oscopy or joint aspiration as clinically indicated. 
Samples were spun and stored at -20^C until assay. IL-17 in serum and SFs was measured 
by ELISA. Elevated levels o f IL-17 were detected in all SF samples across a broad range 
from 4pg/ml to 5175pg/ml. Matched serum in 13 patients contained no detectable levels of 
IL-17 (SF vs. serum: p<0.05). The median concentration o f IL-17 in SF was 46pg/ml 
(Figure 7.1).
7.2 Immunohistochemical detection of IL-17 in PsA SM
Previous studies have indicated that IL-17 is expressed by RA synovium and is produced 
spontaneously in RA synovial cultures (Chabaud, Lubberts et al. 2001). I used 
immunohistochemistry to characterise expression of IL-17 in PsA SM tissue obtained at 
needle artliroscopy and fixed in formalin prior to paraffin embedding. Paraffin embedded 
tonsil was used as control tissue (figure 7.2). Biotinylated polyclonal goat anti-human IL- 
17 antibody was used for IL-17 detection and amplified using ABC system. IL-17 staining 
was detected in 6 o f 10 SM samples (Figure 7.3). Positive staining was obseived 
predominantly in the sublining layer. Quantitation o f positive staining cells was performed 
on the 6 positive sections (Table 7.1).
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Figure 7.1 IL-17 levels are raised in PsA SF
Serum and SFs were obtained from patients with active PsA and assayed for the presence 
o f IL-17 by ELISA. Levels in SFs were significantly higher than serum. IL-17 values are 
expressed on a log scale.
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»Figure 7.2 Immunohistochemical analysis of IL 17 in tonsil
Paraffin embedded sections were fixed and stained with biotinylated anti IL-17 antibody or 
irrelevant primary as control (goat IgG). Primary antibody was detected using avidin/biotin 
complex immunoperoxidase method and diaminobenzidine for colour development.
A, Tonsil negative control (magnification x40) B, Tonsil positive control (magnification 
x40).
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Figure 7.3 lL-17 expressions in psoriatic SM
Immunohistochemical analysis of synovial tissue from a representative PsA patient. 
Paraffin embedded sections were fixed and stained with biotinylated anti IL-17. Primary 
antibody was detected using avidin/biotin complex immunoperoxidase method and 
diaminobenzidine for colour development.
A, PsA SM (magnification x20) B, PsA SM (magnification x40).
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LL SL LA
PsA 1 0 1 na
PsA 2 1 2 2
PsA 3 0 1 na
PsA 4 0 2 1
PsA 5 0 2 1
PsA 6 0 1 1
Table 7.1 Quantification of synovial expression of IL-17
Quantitative expression o f IL-17 was assessed in tissue samples using a scoring system 
agreed between 2 independent observers. 0 = no staining, 1 - 1-10% of nucleated cells 
stained positive, 2=10-25% nucleated cells, 3=25-50% and 4=>50% positive.
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7.3. Functional effects of IL-17 in PsA
Based on the hypothesis that IL-17 might form a link from Thl cell to tissue destruction 
via fibroblast activation, I next determined the functional role o f IL-17 in PsA. To this end, 
I performed a series of experiments with synovium-derived fibroblast like synoviocytes 
(FLS) examining their potential to synthesise cytokines and MMPs following stimulation 
with IL-17.
7.3.1 IL-17 induced IL-6 production by synovial fibroblasts
I initially sought to determine whether IL-17 was capable o f activating synovial FLS 
cytokine release in vitro. FLS were grown as described in chapter 2 from SM obtained at 
needle arthroscopy. FLS were used from passage 3 at which point CD3^ and CD 14^ cells 
were both <1% by FACS analysis. Single cell suspensions o f fibroblasts from the third 
passage were then cultured in the presence o f recombinant human IL-17 or medium alone. 
FLS alone produced a median 1094pg/ml of IL-6 over 24h. IL-6 production was 
significantly increased by the addition of 5ng/p,l IL-17 (FLS alone vs. IL-17: p<0.05, Mann 
Whitney) (Figure 7.4). There has been considerable recent interest in novel IL-10-like 
cytokines that may be T cell derived and that may modulate downstream effector responses 
from stromal cells. IL-22 represents one such novel cytokine that is Thl cell derived and 
that is capable o f activating STAT3 phosphorylation in RA and PsA FLS (Dr A. Crilly 
unpublished observations). I therefore added IL-22 together with, or in the absence o f IL- 
17 to evaluate potential synergy or cytokine interactions. However, over three repetitions,
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there was no demonstrable effect o f IL-22 either upon spontaneous IL-6 release or on IL- 
17 induced IL-6 release (Figure 7.4).
7.3.2 M M P3 in PsA -  regulation by IL-17
MMP3 is a critical regulator of extracellular matrix integrity that is upregulated in a 
number of inflammatory arthropathies. I initially confirmed the baseline expression o f 
MMP3 in the PsA SFs using ELISA. In 6 PsA SF supernatants MMP3 was easily detected 
with median concentration 1079ng/ml (769ng/ml to 1333ng/ml) (Figure 7.5). To further 
investigate this relationship in vitro, PsA SM derived FLS were cultured in the presence or 
absence o f rIL-17 and MMP3 release was measured after 24h. Median baseline production 
of MMP-3 by PsA FLS was 1.7ng/ml. The addition o f 5ng/p.l IL-17 to FLS cultures 
resulted in an increase o f MMP-3 production to 22ng/ml. This increase in MMP-3 
production by exogenous IL-17 was inhibited by 50% in FLS when cultured in the 
presence its neutralising anti IL-17 antibody (p < 0.05) (Figure 7.6).
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Figure 7.4 IL-6 production by fibroblasts stimulated with IL-17 and IL-22
SM derived fibroblasts were grown in 10%FCS and RPMI. Passage 3 fibroblasts were then 
cultured in the presence o f recombinant human IL-17 and IL-22 singly or in combination. 
Medium alone was used to control for spontaneous IL- 6  production by fibroblasts. (* 
p<0.05, Mann Whitney) Representative o f 5 experiments.
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Figure 7.5 PsA SF supernatant MMP-3 levels
MMP-3 content was assessed in SFs from 6  patients with active PsA by ELISA. SF was 
spun free o f cells and stored at -20°C until assay. In all 6  patients there was substantial 
levels o f MMP3 detected.
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Figure 7.6 Effect of IL-17 on M M P3 production by PsA FLS
FLS were cultured in the presence o f IL-17 with or without prior neutralision. Supernatants 
were harvested after 24 hours and MMP-3 levels were detected using standard sandwich 
ELISA. (* p < 0.05, Mann Whitney) representative o f 5 experiments.
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7.4 Discussion
The detection o f IL-17 protein expression in PsA SM and fluid is a novel finding. PsA is a 
unique artln’opathy that has features of both bone formation and bone destruction occurring 
in the same joint simultaneously. The identification of IL-17 is an important observation as 
IL-17 has opposing effects to IFNy on osteoclastogenesis. IL-17 is associated with 
increased expression o f TRAF - 6  that is required for RANK/ RANKL interactions that 
ultimately lead to osteoclastogenesis. The reverse occurs in the presence o f IFNy which 
causes rapid degradation o f TRAF6  leading to overall increased bone formation. It is 
possible that the pattern o f joint involvement seen in different patients with PsA is a 
reflection o f the predominant cytokine in the environment. Correlation of radiological 
appearances with relative synovial expression o f IFNy and IL-17 would have been o f value 
in confirming this hypothesis but was unfortunately beyond the scope of this project.
The regulation of connective tissue degradation in the presence of synovial inflammation is 
largely due to elevated levels o f MMPs secreted by synoviocytes, chondrocytes and 
inflammatory cells. Previous studies have already shown that serum level o f M M Pl, 
MMP3 and MMP9 are increased in patients with RA, particularly with follicular synovitis, 
compared with osteoarthritis (Klimiuk, Sierakowski et al. 2002). Furthermore, it has 
recently been reported that psoriatic skin and synovium express MMP-9 and that this 
expression is greater than in RA synovium (Hitchon, Danning et al. 2002) indicative that 
MMPs are important regulators in synovial and cutaneous inflammation in PsA. However 
the direct contribution of T cells to joint destruction is a matter o f debate. The definition of 
IL-17 as a T cell derived pro inflammatory cytokine sharing properties with IL-1 has led to
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speculation that such IL-17 may also contribute to joint destruction. Studies o f RA 
synovium have demonstrated that IL-17 is capable of inducing MMP-1 release by synovial 
fibroblasts indicating a potential mechanism o f joint damage. As destruction remains the 
major therapeutic target in inflammatory synovitis, the observations that IL-17 may induce 
synovial derived MMP-3 expression may offer an attractive therapeutic target. Although 
the preliminary data suggest that neutralisation o f IL-17 resulted in a reduction of MMP-3 
release by synovial derived FLS, further clarification would be required using escalating 
doses o f neutralising peptide.
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Chapter 8 Discussion
PsA is a clironic inflammatory arthropathy o f unknown aetiology. The combination o f 
deformity and disability pose unique difficulties for those affected. Disease progression 
with time and an increased mortality rate is now recognised. Despite this there is 
significant umnet clinical need manifest by paucity o f understanding o f disease 
pathogenesis, lack o f safe and effective therapies and lack o f rationally designed therapies. 
PsA is easily diagnosed on the basis of inflammatory arthropathy in the presence o f co­
existing skin inflammation and hence should be easier to define and study compared with 
other inflammatory arthropathies. It is therefore rather surprising that it is less well studied 
in terms o f pathogenesis and therapeutic interventions than RA.
Recent studies using biologic agents such as etanercept, infliximab and alefacept appear 
promising. Interestingly however, etanercept and infliximab, were used to treat psoriasis 
and PsA before TN Fa was identified in involved tissues. Their beneficial effects do 
however indicate that the synovial immune response offers an attractive therapeutic target 
(Mease, Goffe et al. 2000). Consequently, current unmet need may be resolved by 
developing a better understanding o f immune events in the joint and beyond. It is well 
established that synovial and cutaneous inflammation in PsA results fiom an intense 
infiltrate of activated T cells (Oitoime 1996) (Braathen, Fyrand et al. 1979). Unfortunately 
however, T cells modulating therapies such as cyclosporin have failed to produce 
significant clinical benefit particularly in PsA. Furthermore, long-term use is hindered by 
nephrotoxicity in both psoriasis and PsA (Olivieri, Salvarani et al. 1997).
The true phenotype o f T cell response in PsA remains controversial. Although the majority 
of evidence points towards a Thl driven disease, conflicting data regarding the magnitude
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of such Thl responses has hindered further developments in this area. I set out to initially 
clarify the phenotype o f Th responses in PsA to clarify this issue. Such studies combined 
with the identification o f regulatory factors for T cell activation were performed to 
contribute to the understanding of disease immunopathogenesis and subsequent generation 
o f rationally designed therapies.
Previous to this work, analyses o f SF in seronegative arthropathies has revealed relative 
paucity of IFNy, the hallmark o f Thl response, compared with RA (Canete, Martinez et al. 
2000). Although IFNy was readily detectable at mRNA level, protein detection by ELISA 
in SFs was seldom present (Ritchlin, Haas-Smith et al. 1998). To address this discrepancy 
in expression, I employed a double antibody teclinique to detect spontaneously secreting 
IFNy cells in the SF and PB of patients with PsA and RA by FACS analysis. This is the 
first time that cells actively secreting IFNy cells have been identified in a human disease 
state. The presence of such a population o f IFNy secreting cells without prior mitogen 
simulation reflects a true Thl response in vivo. This response was o f greater magnitude in 
PsA than in RA reflecting differences in terms o f clinical expression and pathogenesis. The 
presence o f T hl response in PsA was further explored by analysing the presence o f other 
T hl cell specific surface markers CCR5 and IL-18R (Loetscher, Uguccioni et al. 1998; Xu, 
Chan et al. 1998). Such dual expression by SF MCs compared with PB further support the 
predominance o f T hl response in PsA. Clearly one criticism o f these studies would be that 
although IFNy secreting cells were identified, are they truly pathogenic? The ability to 
study these cells is possible using magnetic bead labelling prior to FACS analysis. This 
was a technique that I failed to perform successfully during the time period of this study 
but would have contributed significantly to the proposed hypothesis. By isolating the IFNy
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secreting cells one could phenotype with up to 5 separate cell surface markers using 
spectrophotometry. This would confirm whether the IFNy secreting cells co- expressed 
CCR5 and IL-18R. The technique o f spectrophotometry in my host laboratory was in early 
stages o f development at the time of these studies. Furthermore, by isolating such cells one 
could proceed to study their functional response to cytokine stimulation in terms o f TN Fa 
secretion. The results of these studies would clarify or refute that these cells are truly 
pathogenic in PsA.
The regulation o f Thl responses provides a further means of regulating the inflammatory 
immune response. I next therefore sought to identify the presence of key Thl regulatory 
cytokines IL-12 and IL-18 in the synovial and skin compartments in patients with active 
PsA. Several methods o f targeting regulatory cytokines have been described particularly in 
the case of IL-18 as it serves as a fine tuner o f the Thl response. Soluble receptors, IL-18 
binding protein and IL-18 neutralising antibody are potential agents in blocking IL-18 
induced effector responses. The recently designed 'cytokine traps' can potently block 
cytokines in vitro and in vivo. Traps consist o f fusion between the Fc region o f IgG and the 
extracellular domains of two distinct cytokine receptor components involved in binding. 
They therefore represent a substantial advance in creating novel therapeutic candidates for 
cytokine-driven diseases (Economides, Carpenter et al. 2003).
IL-18 was easily detected at the protein and message level in synovial compartment and 
matched skin from patients with active PsA. Positive double staining using CD6 8  indicated 
that IL-18 was generated in resident macrophages. Both membrane and skin explant 
cultures were capable of producing significant levels of IL-18. These tissue culture 
experiments repeated in the presence o f P2X7 inhibitors would be o f interest as IL-18
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release was shown to be ATP dependant in SF cell culture. One inliibitor (AR- 
C 134170A A) resulted in no inhibition o f IL-18 release detected when added to SF MC 
cultures. As IL-18 fine tunes T hl responses and induces TN Fa release alone, it is a more 
attractive target than IL-12 that is a critical regulator of effector Thl responses. Finally, 
IL-18 in synergy with IL-12 induced IFNy production that was inhibited in the presence of 
p38 MAP kinase inhibitor suggesting that oral MAP kinase inhibitors may be o f potential 
benefit in PsA.
Having identified IL-18 expression in PsA SM and SFs, my host department has now 
commenced clinical trials o f anti IL-18 therapy in vivo.
Having confirmed that T hl responses were likely to be predominant in PsA, I sought 
further clarification by determining the expression of IL-17, a novel Thl cytokine. IL-17 
protein was readily detected in PsA SM and fluids o f patients with active disease. The 
presence of mRNA will be explored in future studies however these data are not available 
at the time o f writing. The co expression o f IL-17 and IFNy may have implications for 
some of the unique radiological features seen in PsA. IL-17 mediates osteoclastogenesis 
via activation of RANK/RANKL via TRAF6  whereas IFNy causes rapid degradation of 
TRAF6  thereby inliibiting bone resorption (Takayanagi, Ogasawara et al. 2000). Our 
preliminary studies indicate that cartilage degradation may occur via IL-17 induced MMP- 
3 production by fibroblasts as described in other rhemnatic disease (Ribbens, Andre et al. 
2000). Significant baseline levels of MMP-3 were detected in all PsA SF samples tested. 
IL-17 was capable o f inducing MMP3 and IL- 6  release by synovial derived fibroblasts that 
was reversed using anti IL-17 neutralising antibody.
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To clarify whether relative expression o f IL-17 and IFNy could affect disease phenotype, I 
would have liked to correlate radiological features with levels o f IFNy and IL-17 in a 
subset o f patients over time. Those with arthritis mutilans would be a particularly 
interesting group as one would expect high levels o f IL-17 in the presence o f relatively low 
levels o f IFNy. To extend this theory, the differential frequency and phenotype o f Thl 
cells obseiTcd in PsA compared with RA may explain the observed differences in disease 
expression such as the typical ‘pencil in cup’ deformity that is classical feature of PsA.
Contrary to the literature in psoriasis implicating a role for NKT cells in disease 
pathogenesis, I did not detect an increase in this population within the SF o f PsA patients 
compared with peripheral blood. There are several markers o f NKT cell that can be 
employed to detect expression in tissue and fluids. I measuied TCR V p ll ,  however time 
constraints prevented the exploration of other NKT cell specific markers such as TCR 
V a24 or CD161. The inability of agalcer a synthetic glycolipid recognised by NKT cells, 
to stimulate proliferation, TN Fa o f IFNy production by PsA SF cells further supported that 
NKT cells do not seem to play a major role in PsA pathogenesis.
PsA and psoriasis are diseases that affect a significant proportion of our population 
however those factors triggering onset and perpetuation of skin and joint inflammation 
have yet to be defined. Clearly the most critical discovery would be the identification of 
the triggering antigen. This may be achievable in the future however until such times, it is 
essential that we acquire a better understanding o f disease pathogenesis to provide a 
rational basis for the development o f future treatments. Although the data presented in this 
thesis are suggestive o f an association o f Thl responses with psoriasis and PsA, the
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numbers of tissue samples studied were small. The clinical phenotype of the cohort, 
disease duration and disease modifying therapy may alter the results obtained. Clearly 
more work is required in this field to correlate the preliminary findngs with a more defined 
cohort.
The work outlined in this thesis has contributed to the understanding o f this disease and as 
such will hopefully lead to the development o f novel therapies in the future.
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Appendix A
1. Phosphate buffered saline (PBS, x 10 stock)
80g NaCl
2g KCL 
11.6gNaH2P04 
2 g KH2PO4 
Adjust to pH7.4
Autoclave and store at room temperature
2. PBS/Tween 
0.5ml Tween 
1000ml PBSxl
3. Coating buffer (ELISA)
0 .1M N aH C O 3, p H 8 .2
4. TBS
900ml 0.9% NaCl
100ml 50mM Tris-HCl, pH 3.6
50mM Tris-HCl
Add cone HCl to 25ml 0.2M tris-HCl to pH 7.36 
Make up to 100ml with dH2 0
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Appendix B
191
Name.
HEALTH ASSESSM ENT QUESTIONNAIRE
m / m / i 2 i o i o i 3Today's date
MONTH DAY YEAR
Please tell us how your arthritis affects your ability to carry out your daily activities.
Please place an "X" Inthebox B  which best describes your usual abilities OVER THE PAST WEEK:
DRESSING & GROOMING
WITHOUT ANY WITH SOME
DIFFICULTY DIFFICULTY
WITH MUCH 
DIFFICULTY
UNABLE 
TO DO
Are you able to:
Dress yourself, including shoelaces and buttons? Q
Shampoo your hair?
ARISING
Are you able to:
Stand up from a straight chair?
Get in and out of t>ed?
EATING
Are you able to:
Cut your meat?
Lift a full cup or glass to your mouth? 
Open a new mUk carton?
WALKING
Are you able to:
Walk outdoors on flat ground? 
Climb up five steps?
□
□□
□□□
□□
□□
□□
□□□
□□
□□
□□
□□□
□□
□□
□□
□□□
□□
Please check any AIDS OR DEVICES that you usually use for any of the above activities:
□  Devices Used for Dressing □  Built up or special utensils □  Cmtches
(button hook, zipper pull, etc.) [ ]  Cane [ ]  Wheelchair
n  Special or twilt up chair d  Walker
Please check any categories for which you usually need HELP FROM ANOTHER PERSON:n Dressing and Grooming d Arising d Bating d Walking
- 1- 4288014401
Please place an "X" In the box H  which best describes your usual abilities OVER THE PAST WEEK:
HYGIENE
Are you able to:
Wash and dry your body?
Take a tub bath?
Get on and off the toilet?
Are you able to:
WITHOUT ANY WITH SOME WITH MUCH UNABLE
DIFFICULTY DIFFICULTY DIFFICULTY TO DO
□ □ □ □□ □ □ □□ □ □ □
= □ □ □ □
□ □ □ □
□ □ □ □□ □ □ □□ □ □ □
□ □ □ □□ □ □ □□ □ □ □
bag of sugar) from above your head?
Bend down to pick up clothing from the floor?
Are you able to:
Open car doors?
Open previously opened jars? 
Turn faucets on and off?
ACTIVITIES
Are you able to:
Run errands and shop?
Get in and out of a car?
Do chores such as vacuuming or yard work?
Please check any AIDS OR DEVICES that you usually use for any of these activities:
□  Raised toilet seat □  Bathtub bar □  Long-handled appliances for reach
□  Bathtub seat □  Long-handled appliances in bathroom □  Jar opener (for jars previously opened)
Please check any categories for which you usually need HELP FROM ANOTHER PERSON:
□  Hygiene □  Reach □  Gripping and opening things □  Errands and chores
How much pain have you had because of your arthritis IN THE PAST WEEK:
PLACE A SINGLE VERTICAL MARK THROUGH THE LINE TO INDICATE THE SEVERITY OF THE PAIN
NO
PAIN
SEVERE
PAIN
100
- 2-
0669014400
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